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ABSTRACT 
The hypothesis of this work was whether IGRT could be safely implemented for clinical 
use in a busy oncology centre. I aimed to study a number of questions that remain 
unresolved in the current literature regarding safe and optimised implementation of 
IGRT techniques.  
The first study undertaken was the calculation of a local set up margin using two widely 
recognised  margin  recipes.  This  involved  the  assessment  and  analysis  of  multiple 
images belonging to 100 patients. This allowed progression onto the next project which 
was assessment of the optimal safe method of delineation of 4DCT. The most efficient 
method was compared to gold standard. 
At  this  point  a  different  aspect  of  the  radiation  process  was  assessed,  namely 
verification. A feasibility study of a simple, efficient form of imaging for use in review 
of a particular error was performed. This also involved the use of a novel tool which 
required  independent  assessment.  This  progressed  into  a  further  study  of  a  larger 
number of patients using this tool and the images assessed previously to verify a novel 
form of radiation delivery. 
Lastly  a  planning  study  was  performed  to  quantify  the  clinical  benefit  of  another 
delivery system. This involved the delineation and planning of a large number of radical 
lung patients with standard radiation treatment and the novel radiation treatment and 
an assessment of the potential clinical benefits.   
The work presented in this thesis has answered some specific questions in IGRT in lung 
cancer,  and  contributed  both  locally  and  in  the  wider  lung  cancer  community  to 
increasing the use of IGRT in lung cancer.  - iii - 
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1. INTRODUCTION TO LUNG CANCER AND LUNG CANCER RADIOTHERAPY 
 
1.1 Introduction to Lung Cancer 
 
1.1 Lung Cancer  
 
Lung Cancer remains the UK’s commonest cause of cancer death accounting for 1 in 5 
deaths. In the UK, around 35,000 people die from lung cancer annually, with around 
41,000 diagnoses. It is the second most common cancer in men after prostate and the 
third most common cancer in women after breast and bowel cancer [1]. Rates of lung 
cancer in Scotland are among the highest in the world, reflecting the high smoking 
prevalence [2]. Other factors such as poor diet, exposure to industrial carcinogens and 
air pollution may also contribute [3,4]. In addition, in the West of Scotland, about 6% of 
male lung cancers are attributed to asbestos exposure associated with the ship-building 
industry  [5].  There  is  a  large  population  of  deprived  patients  with  multiple  co-
morbidities making treatment more challenging and long term survival more difficult to 
achieve [6].  
 
Treatment is dictated by the tumours pathology and staging. There are other factors 
such  as  performance  status,  co-morbidities,  previous  medical  diagnosis,  previous 
treatment and pulmonary function tests that are all taken into consideration in the 
treatment decisions; however these are individually assessed in each case as they can 
vary widely.  
In terms of pathology, this work will concentrate on non-small cell lung cancer, the 
main  types  of  which  are  squamous  cell  carcinoma,  adenocarcinoma  and  large  cell 
carcinoma. Although the pathology of a NSCLC tumour is increasingly being used to 
dictate  systemic  treatment  options  with  chemotherapy  and  biological  agents,  in 
radiotherapy,  all  pathological  sub-types  are  treated  with  the  same  radiotherapy 
techniques.  
Staging is determined by diagnostic imaging with computed tomography (CT), positron 
emission tomography (PET) and histological sampling of lymph nodes where necessary - 2 - 
with either transbronchial approach or at mediastinoscopy [7,8]. Staging is reported 
according to the International Staging System, first published in 1986 by the American 
Joint  Committee  on  Cancer  (AJCC)  and  the  Union  Internationale  Contre  le  Cancer 
(UICC) [9]. Table 1-1 shows the international staging system for lung cancer. 
 
 
1.1.2 Management of NSCLC.  
 
In NSCLC, only patients with Stage I-IIIB can receive treatment with curative intent. 
This study concentrates on this group. These patients have a primary tumour with or 
without local nodes all of which can be encompassed within a radiotherapy field.  
 
The gold standard management of Stage I and II NSCLC is radical surgery, with 5-year 
survival in pathologically staged patients with Stage IA, IB, IIA and IIB patients reported 
as 74%, 58%, 46% and 36% [9]. Unfortunately due to a number of issues, particularly 
poor pulmonary function and co-morbidities, the British resection rate is only 11% [10]. 
For  medically  inoperable  patients,  conventionally  conformal  radiotherapy  is  the 
standard of care in the UK and produces 5-year survival rates of between 0-42% [11]. As 
these patients are often frail with multiple co-morbidities, a different endpoint is often 
used: local control rate. The local control rate is a measure of the number of patients 
who have no recurrent disease either in the area irradiated, the surrounding normal 
lung or the regional lymph nodes. The local control rate in Stage I/II NSCLC patients 
treated  with  conformal  radiotherapy  is  30-94%  [11].  There  is  however  international 
agreement that for small tumours with no lymph node involvement, stereotactic body 
radiotherapy (SBRT), which has local control rates of 91.8%, 95% and 93%, is the gold 
standard for medically inoperable patients in selected patients [12,13,14]. This will be 
discussed further in 4.1.1.  
 
The management of Stage III NSCLC is much less clear cut; however there is consensus 
that  multimodality  treatment  is  required.  A  combination  of  chemotherapy  and 
radiotherapy are used, either concurrently or sequentially occasionally with the - 3 - 
Table 1-1. The international staging system for NSCLC, 2009.  
 
  T1a  Tumours ≤ 2cm 
  T1b 
 
Tumours > 2cm to ≤ 3cm 
 
  T2  Tumour involves the main bronchi; Tumour has caused partial collapse of a lobe;  
The tumour has grown into the inner lining of the visceral pleura;  
The primary tumour falls into the size categories below: 
   T2a  Tumours > 3cm to ≤ 5cm 
   T2b 
 
Tumours > 5cm to ≤ 7cm 
 
  T3   Tumours > 7cm; Additional tumour nodules in primary lobe;  
Any tumour < 2cm from the carina. 
  T4  Additional tumour nodules in ipsilateral lung; Tumour invading mediastinal structures. 
   
  N0  No involved lymph nodes. 
  N1  Involved hilar lymph nodes. 
  N2  Involved mediastinal lymph nodes. 
  N3  Involved contralateral lymph nodes. 
   
  M1a  Additional tumour nodules in contralateral lung; Malignant effusions; Pleural nodules. 
  M1b  Distant metastatic disease outwith the lung / pleura. 
  
 
 
 
 - 4 - 
 
  Stage IA 
 
T1a N0 M0; T1b N0 M0 
  Stage IB  T2a N0 M0 
 
  Stage IIA 
 
T1a N1 M0; T1b N1 M0; T2a N1 M0; T2b N0 M0 
  Stage IIB 
 
T3 N0 M0; T2b N1 M0 
 
  Stage IIIA  Any T N2 M0; T3 N1 M0; T4 N0 M0; T4 N1 M0 
  Stage IIIB  
 
Any T N3 M0; T4 N2 M0 
 
  Stage IV  Any T Any N M1 - 5 - 
addition of surgery on completion. In our centre and throughout the UK, radical chemo-
radiotherapy is treatment of choice. For a selected group of fit patients, concurrent 
chemo-radiotherapy provides a 5-year overall survival benefit of 4.5% over sequential 
treatment [15], however for those patients with large tumour bulk or who are less fit, 
sequential treatment is delivered. Irrelevant to whether the patient receives sequential 
or concurrent chemo-radiotherapy, the radiotherapy remains the same.  
 
The  dose  prescribed  in  our  centre  and  most  commonly  in  the  UK  for  radical 
radiotherapy in all stages, is 55Gy in 20 fractions over 4 weeks which most oncologists 
believe is biologically equivalent to a dose of approximately 64Gy in 32 fractions over 6 
½ weeks. Most centres worldwide however, deliver 2Gy doses daily to 60-66Gy in node 
positive disease and significantly higher doses to Stage I tumours using SBRT which will 
be discussed in the next section. There have only been three, large, phase III, dose 
comparison trials ever conducted [16,17,18]. These can be interpreted in many ways, 
however the widely accepted conclusions are that in 2Gy fractions, the dose must be 
≥60Gy.  
 
 
1.2 Current Radiotherapy techniques 
 
1.2.1 CT Simulation 
 
The  CT  simulator  is  a  conventional  diagnostic  CT  scanner  with  special  radiotherapy 
planning software and LASERS to aid patient set-up. To ensure what is delineated on 
the planning scan is as close to what is treated as possible, immobilization techniques 
are  used.  The  patients  are  set  up  at  every  simulation  and  treatment  session  using 
Sinmed  Posirest  Thoracic  Board  (Sinmed  BV,  The  Netherlands)  and  a  knee  support. 
Figure 1-1 shows the patient in treatment position with the thoracic board. During CT 
simulation,  the  patient  is  positioned  for  treatment  and  to  reproduce  the  position, 
marks  are  drawn  on  skin  (one  anteriorly  and  2  each  side  laterally)  where  lasers 
representing  the  treatment  centre  fall.  At  check  simulation  if  everything  lines  up - 6 - 
correctly these marks are then tattooed to the patient so that during treatment, these 
tattoo’s can be used to set the patient up using the lasers. In patients known to have 
mediastinal disease 50ml intravenous iodinated contrast is administered at CT image 
acquisition to enable easier visualisation of the lymph nodes [19].  
 
1.2.2 Delineation  
 
The  objective  of  radical  radiation  treatment  is  to  treat  all  of  the  disease  to  a 
therapeutic dose level. This is achieved by firstly defining a planning target volume 
(PTV) by following the principles of ICRU 50/62 [20,21]. The delineation of the planned 
target  volume  (PTV)  is  performed  by  the  clinician.  There  are  several  steps  in  the 
process  that  are  all  in  accordance  with  ICRU  50  and  62.  The  general  steps  for 
delineation in lung radiation oncology are as follows:  
1) Initially the gross tumour volume (GTV) is delineated; this is the visible extent 
of the malignant tumour. In our centre different clinicians use different window 
levels however ideally a uniform window width and level is required to minimize 
interclinician variation. EORTC guidelines suggest window width = 1,600 and level 
= -600 for parenchyma and window width = 400 and level = 20 for mediastinum 
[22]. 
2)  A  margin  for  local  subclinical  spread  of  the  disease  is  given  to  create  the 
clinical target volume (CTV). Although this margin in lung cancer is usually 5mm, 
the  most  robust  paper  from  Giraud  et  al.  [23]  suggests  that  the  microscopic 
margin should be 6mm and 8mm for squamous and adenocarcinomas respectively. 
3) A further margin to create the internal target volume (ITV) is to ensure that 
the tumour is covered throughout the fraction as tumours can change in size, 
shape and position due to internal structure motion. In lung cancer the largest 
movement  is  due  to  respiration  induced  tumour  motion,  and  hence  a  larger 
margin  is  given  craniocaudally  than  anteriorly,  posteriorly  and  laterally  as 
respiration induced tumour motion is maximal in the cranio-caudal direction. 
4) Finally, a margin for set-up error encompassing both systematic errors, due to 
different set-up on the CT simulator, and random set-up errors that can occur on - 7 - 
a day to day basis during treatment, to create the planned target volume (PTV). 
This set-up margin can be calculated using equations by Van Herk et. al. [24] and 
McKenzie et. al. [25]. This calculation is explained and performed later on in this 
paper. 
 
In  routine  clinical  practice  in  our  centre,  it  is  normal  to  combine  some  of  these 
margins. The GTV is delineated and then a single additional margin that encompasses 
CTV, ITV and PTV margins is added to create the PTV. Craniocaudally 20mm is used, 
anteriorly posteriorly and in both directions laterally 15mm is used. This creates the 
PTV, which is the volume that we attempt to irradiate with between 95 to 107% of the 
prescribed dose. 
 
The technologists in the physics department delineate the organs at risk (OAR), which 
are those normal tissues that are sensitive to radiation. The dose to these organs must 
be restricted. This can usually be achieved by optimisation during planning. In lung 
cancer radiation the OAR are the normal lung, the spinal cord, the oesophagus and to a 
lesser  extent  the  heart.  In  our  centre,  only  the  normal  lung  and  spinal  cord  are 
delineated routinely and taken into consideration when choosing the best plan. It is not 
routine clinical practice to outline the oesophagus and heart in our centre as in the 
view of our clinicians we do not have a high rate of oesophageal or cardiac adverse 
effects. As radical treatment becomes more toxic with increased doses and concurrent 
chemotherapy,  outlining  of  these  organs  will  no  doubt  become  standard  as  it  will 
become increasingly important to alter plans to limit the dose to these organs. The 
measures that are reviewed for the lung are the V20 lung and the mean lung dose (MLD) 
[26]. The V20 lung is the volume of “normal” lung that receives ≥20Gy. The “normal” 
lung is calculated by combining the volumes of the left and right lung, then excluding 
any lung tissue that is covered by the PTV. This measure correlates with the likelihood 
of radiation pneumonitis and thereafter long term lung damage. The mean lung dose 
(MLD) is the mean dose to the left and right lung combined. The spinal cord has a 
maximum dose cut off; this is achieved by ensuring one of the beams misses the cord 
entirely.   - 8 - 
Figure 1-1. The patient immobilised in treatment position with a Sinmed Posirest 
Thoracic Board. 
 - 9 - 
 1.2.3 Planning and Plan calculation 
 
Planning of 3D conformal radiotherapy lung cancer is usually performed with three to 
five photon beams and multi-leaf collimators that allow shaping of the beams. A typical 
radical plan involves one wedged anterior beam with an anterior oblique and further 
wedged  posterior  oblique  both  on  the  side  of  the  tumour.  Choice  of  gantry  angle 
depends on the position of the spinal cord in relation to the tumour as one of the 
beams must miss the cord entirely to maintain an acceptable dose. Non-coplanar beams 
are rarely used.  
Plan  calculation  in  our  centre  is  performed  using  the  Varian  Eclipse  pencil  beam 
algorithm (Version 8.6), however there are many other planning systems and different 
algorithms can be used. The plan is then optimised by adjustments to wedge angles, 
beam  weights  and  gantry  angles  to  cover  the  PTV  with  between  95-107%  of  the 
prescribed dose and limit the dose to organs at risk as much as possible. If following 
plan calculation the peripheries of the PTV are underdosed, boost fields to these areas 
can be added. The ability to create the best plan depends on the judgement, skill and 
experience of the operator. Occasionally there is no plan that maintains therapeutic 
dose within the PTV and has an acceptable OAR profile. In these cases, a number of 
possible plans with varying amounts of PTV covered or doses to OAR are created and it 
is the decision of the clinician where it is more clinically appropriate to compromise. 
Figure 1-2 shows a typical treatment plan in lung cancer radiotherapy.  
As described above, the dose prescribed in our centre for a radical treatment is 55Gy in 
20 fractions over 4 weeks or, if chemotherapy is being used concurrently, 66Gy in 33 
fractions over 6 ½ weeks.  - 10 - 
Figure 1-2. A standard, 3D conformal radiotherapy lung treatment plan. 
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 1.2.4 Check Simulation 
 
There are three purposes of check simulation: 
1) Verification of the patient’s position at CT simulator is done by performing a 
bony match between a kV simulator image taken at check simulation, and the 
digitally  reconstructed  radiograph  (DRR)  created  from  the  planning  CT.  Both 
orthogonal images for iso-centre verification and / or ‘beams-eye view’ of the 
actual treatment fields can be checked. If any shift is required this is performed. 
A number of radiotherapy departments are moving to eliminate this and move 
directly to pre-treatment verification on the linear accelerator (LinAC). 
2) To check tumour motion, an anterior-posterior fluoroscopic image is produced 
on the check simulator, and provided the tumour can be visualised on kV image, 
this  allows  assessment  of  the  respiration-induced  tumour  motion,  if  tumour 
appears to move out of the PTV, re-planning is required.  
3) Finally, if all the previous checks are satisfactory, the tattoos are performed 
laterally and at midline as discussed above to allow set up with lasers during 
treatment.  
 
 
1.2.5 Treatment and Verification 
 
Patients are immobilised as on the CT simulator and aligned according to tattoos and 
lasers. The treatment is delivered on a daily basis.  
Verification is required during treatment as any error in set-up may cause a failure to 
irradiate all of the disease or over-irradiation of normal/sensitive tissues. Verification 
is currently performed with images acquired using the treatment machine, taken on 
days 1, 2, 3, 8 and 15, which are matched to the DRR images using bony landmarks. Any 
deviation  from  the  position  at  planning,  is  retrospectively  considered  and  a  shift  is 
made if felt appropriate for future fractions.   
 
 - 12 - 
Two different images are taken routinely, each preferred by different clinicians.  
1) Orthogonal “iso-images” are single MV exposure images in both the anterior-
posterior (AP) and lateral direction. These can be acquired for “on-line” or “off-
line” review (the difference will be discussed below). These are compared to the 
same AP and lateral DRRs created from the planning CT, that were reviewed at 
check simulation, and any major errors in patient positioning can be identified. 
These  images  are  preferred  by  some  clinicians  because  they  image  the  whole 
thorax in order to encompass rigid structures such as the spine that can be easily 
compared to the DRR. In addition, clinicians are more accustomed to viewing and 
identifying  structures  in  AP  and  lateral  fields  rather  than  oblique  fields.  One 
exposure of the treatment machine for the acquisition of an iso-image delivers 
around 4mSv per exposure. 
2) Another set of machine images, are “dual exposure images”. They are created 
using  a  combination  of;  a  fraction  of  the  exit  dose  of  the  megavoltage  (MV) 
treatment beam, during an actual treatment; and an additional exposure after 
treatment of the same field with an additional 20mm margin. This allows the 
more heavily exposed treatment field to be seen in the context of the adjacent 
normal tissue structures. Together these two images create a “double-exposure”. 
The images can only be produced from the gantry angle of the beam, therefore 
are always beams eye view (BEV) images, as some of the image is obtained using 
the  treatment  beam.  It  is  often  difficult  to  identify  structures  in  the  double-
exposure  to  compare  to  the  DRR  because  fields  can  be  small  and  the  low 
differential absorption of MV X-rays in tissue gives them a similar appearance and 
hence  makes  it  difficult  to  differentiate  between  structures.  Furthermore 
clinicians are not accustomed to looking at oblique fields.  
 
The majority of verification at present occurs “off-line”, which is a term used when the 
images  are  reviewed  after  the  radiation  has  been  delivered.  During  off-line 
verification, the operator takes into account all shifts from CT planning position in all 
previous fractions and generates a decision (to correct or not and if so by how much) 
for the setup of subsequent fractions. The general guideline in our centre is that if the - 13 - 
bony  landmarks  are  misaligned  by  less  than  5mm  no  action  is  taken,  if  there  is  a 
consistent  shift  of  5mm  in  one  direction  a  permanent  shift  is  made.  If  there  are 
continued concerns about patient set-up, further iso-images can be taken. If there is 
concern that the patient is moving position daily, “on-line” iso-images can be taken. 
On-line images are those taken prior to treatment, with a shift to the DRR position 
performed prior to treatment. Although iso-image can be performed on-line, the beams 
eye  view  double-exposure  images  cannot,  as  they  are  created  using  the  treatment 
beam. This technique has many limitations and many discrepancies remain between 
what  is  planned  and  what  is  delivered  [27].  More  rational  and  objective  off-line 
verification approaches are the “shrinking action-level” protocol [28] or the “no action-
level”  protocol  [29]  which  have  shown  to  reduce  systematic  errors  more,  with  less 
imaging required.  Figure 1-3 gives an example of a BEV EPID image, and some MV iso-
images.   
 
 
1.2.5 Potential Errors with current radiotherapy techniques 
 
Errors are divided into systematic errors and random errors. A systematic error is an 
error  that  is  not  determined  by  chance  but  is  introduced  by  an  inaccuracy  in  the 
system. Systematic errors are consistent throughout the radiation treatment. A random 
error can happen during any treatment day as a result of an unforeseen difference to 
patient  or  treatment  on  that  day.  There  are  a  number  of  potential  systematic  and 
random errors in lung cancer radiotherapy.  
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Figure 1-3. (a) - A BEV EPID image; (b) - An anterior iso-image; (c) - A lateral iso-image  
   
 
 
(a) 
(b) 
(c) - 15 - 
Potential systematic errors: 
1)  During  the  CT  simulation,  the  main  possible  error  is  an  error  in  set-up  or 
tattooing which would result in consistent incorrect set-up during treatment eg. 
CT table sag, couch sag or LASER misalignment.  
2) A number of possible errors arise from the delineation process. To understand 
these it is important to know how much of the composite margin (20mm cranio-
caudal  and  15mm  lateral  and  anterio-posterior)  is  derived  from  each  of  the 
individual  margins  for,  subclinical  disease  (CTV),  internal  movement  (ITV)  and 
set-up errors (PTV). I will hence discuss each margin individually with the possible 
errors: 
•  The GTV delineated by different clinicians can vary greatly and it has 
been shown that even experienced clinicians are capable of voluming areas 
where  there  is  no  gross  tumour  or  omitting  areas  where  there  is  gross 
tumour [30]. This would result in irradiation of normal tissue or missing 
tumour tissue. This classifies as a systematic error. It is very difficult to 
allow for this error as an addition to a margin, as although there are small 
differences in where to place a delineation line around a tumour, the larger 
differences in lung cancer arise from decisions on whether or not to include 
a lymph node that has not been biopsied. To include this in a margin is 
impossible as lymph nodes are in different positions and of different sizes. 
It is therefore not encompassed in any margin. Previously elective nodal 
irradiation dealt with this issue, however it is now thought superior to only 
include malignant nodes within the GTV. Usual practice has been to outline 
all nodes greater than 1cm. Local relapse alone in adjacent nodes following 
radiotherapy is rare [31,32], probably due to some of the surrounding nodes 
being partial irradiated in the entrance and exit beams [33]. 
•  The GTV to CTV margin is currently 5mm. This margin is accepted as 
standard for ease and to allow a coherent approach. In reality, the most 
significant  paper  on  microscopic  disease  in  lung  cancer  has  the  margins 
being 6mm and 8mm for squamous and adenocarcinomas, respectively [21]. 
The majority of centres worldwide leave margins of 5mm, however it is - 16 - 
accepted  that  different  patients  have  different  degrees  of  microscopic 
invasion [34] and therefore as we cannot assess it in individual patients, it 
will inevitably be over or under estimated in many resulting in a systematic 
error.   
•  The  CTV  to  ITV  margin  used  in  our  centre,  is  currently  a  standard 
margin  that  is  added  to  all  tumours.  It  is  well  accepted  however  that 
respiration-induced tumour motion is unpredictable and varies enormously 
between  patients  [35,36,37].  Hence  a  standard  margin  will  result  in 
systematic error due to underestimation of movement or overestimation of 
movement  for  the  majority  that  are  at  variance  with  the  standard 
“population-based” margin allows.  
•  The ITV to PTV margin, or set-up margin, is a margin chosen by the 
radiation oncology team, based on experience and judgment drawn from 
observation and evaluation of the risk of failure and complications. This is 
currently  what  we  use  at  the  Beatson.  It  can  also  be  calculated  for  an 
individual department using the McKenzie et al [23] or Van Herk et al [22] 
margin equations. There may be a systematic error introduced at this point 
if has been over or underestimated. 
•  In the ICRU 62 report, there is extensive discussion on how to add these 
margins together. If simple linear addition is used, it is recognised that the 
PTV may be inappropriately large. It is up to the local radiotherapy team to 
use their experience and judgement in deciding the method of addition of 
these margins.  
3) During the plan calculation process, if an error occurred in creating the plan, 
or disseminating the information to check simulation or the treatment room a 
systematic error could occur.  
4) During check simulation again if the patient is set-up incorrectly or tattooed 
incorrectly a systematic error would be introduced. 
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Potential random errors: 
1) If the patient is set-up incorrectly on a particular day. This would result in a 
random error that fraction. 
2)  If  the  patient’s  tumour  changes  position  over  the  course  of  four  weeks  of 
treatment due to re-inflation of a lung or inflammation of the surrounding normal 
lung, this is not consistently present from the beginning but could be consistently 
present  towards  the  end  of  treatment  therefore  it  could  be  considered  both 
random or a systematic error.  
3)  If  the  patient  loses  weight  or  relaxes  into  the  treatment  couch,  this  could 
cause a variation from planning and hence a random error, however as with the 
tumour migration, if this error consistently becomes a problem, it could also be 
viewed as a systematic error.  
 
Although our current technique of 3D conformal radiotherapy is relatively standard, 
section 1.2.5 highlights many limitations. The current verification technique of offline 
MV images can only reduce the systematic errors occurring due to a change in patient 
position. It does not deal with any other errors. Many of the potential errors highlighted 
above  can  be  reduced  with  the  use  of  other  imaging  techniques  and  thus  the 
introduction of Image Guided Radiotherapy (IGRT). 
 
 
1.3 Image Guided Radiotherapy 
 
1.3.1 What is Image Guided Radiotherapy? 
 
Image  Guided  Radiotherapy  (IGRT)  is  the  use  of  different  imaging  techniques  to 
improve  on  the  three  main  steps  of  radiotherapy:  delineation,  planning  and 
verification. IGRT can improve target coverage, and facilitates a reduction in the large 
margins, that we traditionally use to allow for unknown or large errors, with a view to 
reducing dose to organs at risk (OAR). It can also facilitate alternative planning and - 18 - 
delivery techniques allowing us to escalate the dose and thereby improve the chance of 
local control.  
A number of developments in radiotherapy have emphasised a need for improved IGRT: 
• Planning has become more conformal with the advent of intensity modulated 
radiotherapy (IMRT), arc therapy such as RapidArc (Varian Medical Systems, Palo 
Alto, Ca, USA) and tomotherapy (Tomotherapy Incorporated, Madison, WI, USA).  
• With  increasing  interest  in  dose  escalation,  accurate  target  coverage  and 
sparing  of  organs  at  risk  become  more  important,  as  inaccuracies  have  more 
consequences with bigger doses.   
• With some of the new delivery techniques, fall off doses around the PTV are 
becoming much steeper. As the risk of missing the target becomes greater there 
is a real need to use imaging techniques maximally to target the PTV better  
 
 
1.3.2 Imaging techniques used in CT simulation and Delineation 
 
1.  PET/CT 
The  role  of  positron  emission  tomography  (PET/CT)  for  evaluation,  treatment  and 
follow up of lung cancer patients is rapidly increasing. PET/CT scans make use of the 
fact  that  most  lung  cancers  have  increased  activity  of  glucose  transporters  and 
increased  hexokinase  activity  compared  with  normal  cells.  A  radioactive  agent, 
fluorodeoxyglucose (FDG) is delivered to the patient. Due to the increased activity of 
glucose transporters and hexokinase activity, it accumulates at a higher rate in lung 
cancer cells than the normal tissues. Images taken after FDG administration allow easy 
localisation of gross tumour as most deposits of tumour measuring around >1cm show 
up as a “hot lesion” on the scan. FDG labelled with the positron-emitting isotope F-18, 
is the radiopharmaceutical of choice for imaging lung cancer. The intensity of a “hot 
lesion”  on  PET,  represents  the  FDG  uptake  and  can  be  quantified  using  the 
standardized uptake value (SUV). The SUV is derived by dividing the concentration of F-
18 in the tumour, measured in Bq/gm, by the injected activity per unit body weight.  
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In NSCLC, PET/CT is increasingly used in a number of settings:  
a) To evaluate undiagnosed pulmonary masses, with 96.8% and 77.8% specificity 
and sensitivity respectively [38]. 
b) To stage NSCLC in the mediastinum with a view to dictating therapy as there is 
90% specificity and 85% sensitivity in the mediastinum [39].  
c) To detect distant metastatic disease to prevent radical treatment when it is 
inappropriate,  PET/CT  can  identify  distant  metastasis  in  an  additional  12%  of 
patients  who  have  been  staged  with  Stage  I  disease  with  all  other  standard 
imaging techniques [40]. 
d) To predict response following radical radiotherapy or chemoradiotherapy [41]. 
e) The SUV level can be used as a prognostic indicator [42]. 
f) For use in the delineation process, described in detail below.  
 
The  use  of  PET/CT  in  the  delineation  process  is  becoming  more  prevalent  although 
there  are  a  number  of  unresolved  issues  and  significant  potential  for  further 
development. In routine clinical practice, the majority of clinicians use it as a tool to 
localise  areas  of  gross  tumour.  There  is  good  evidence  that  the  use  of  PET/CT  for 
localisation  can  both  increase  and  decrease  volumes  [43].  This  is  logical  because 
PET/CT can both upstage and downstage mediastinal lymph nodes. In addition it can 
assist in deciding how much opacified lung is active tumour and how much is collapse or 
consolidation.  Its  use  has  also  been  reported  to  reduce  interclinician  variations  in 
delineation  [44]  and  a  further  paper  compared  PET/CT  delineations  to  pathological 
specimens and found that using the additional information of a PET/CT improves target 
coverage from 75% to 89% [45]. There are three different ways that the PET/CT can be 
used for localisation:  
a)  PET/CT  and  planning  CT  can  be  co-registered  so  that  they  are  portrayed 
simultaneously at the planning computer terminal however due to the concerns 
regarding  image  registration  and  spatial  resolution  this  is  not  available  in  all 
centres.  
b) A PET/CT scan can be used as a planning scan if the CT component is of an 
acceptable  quality,  however  many  patients  in  the  UK  continue  to  receive - 20 - 
sequential  chemo-radiotherapy  and  it  is  not  possible  to  perform  a  planning 
PET/CT after neo-adjuvant chemotherapy due to inhibition of SUV uptake by the 
tumour stunning.  
c)  Most  centres  have  the  PET/CT  and  the  planning  CT  on  adjacent  computer 
screens and try to relate in information of the PET/CT onto the planning CT.  
 
Another way in which PET/CT can be used for delineation is for automatically outlining 
the GTV using image segmentation methods that have primarily been based on either a 
threshold value (a percentage of SUV max) [46] or as an absolute SUV [47]. However 
consensus over an absolute ideal value has not been reached. A further limitation is 
that all image segmentation tools require clinical review and adjustment afterwards, 
reducing the time saving benefits offered by image segmentation.  
 
Finally  there  is  much  interest  in  the  possibility  of  “dose  painting”  [48].  NSCLC  are 
heterogeneous and there is evidence confirming that areas of higher SUV uptake are 
the areas where local relapse is more likely [49]. Dose painting involves using a PET/CT 
during  planning  to  deliver  a  bigger  dose  to  those  areas  with  higher  SUV  levels.  An 
alternative approach uses data from a PET/CT scan towards the end of radiotherapy 
treatment and delivering a boost of radiotherapy to the areas with highest SUV levels 
[50]. 
In summary, there is little controversy regarding the use of PET/CT to aid gross tumour 
localisation  and  there  is  evidence  confirming  the  benefits,  however  other  uses  of 
PET/CT in delineation continue to be research based and should not be used out with 
that setting.  
 
 
2.  4DCT simulation 
Four-dimensional CT (4DCT) or respiration-correlated CT scan is a single investigation 
generating  spatial  and  temporal  information  on  mobility  [51,52].  It  permits  organ 
motion to be observed and quantified. Previously the CTV to ITV margin was a set, 
population based margin, added arbitrarily to all patients. However as discussed above, - 21 - 
it is well recognised that the intra-fraction tumour motion of each patients’ tumour 
cannot be predicted. With a 4DCT, the intra-fraction tumour motion can be visualised 
and therefore an individualised margin, specific for each tumour, can be added. 4DCT 
has  been  shown  to  be  a  better  method  of  assessing  respiratory  movement  than 
previously  used  fluoroscopy  [53]  or  the  use  of  six,  standard  3DCT’s,  in  combination 
[54].  The  use  of  4DCT  to  individualise  the  CTV  to  ITV  margins  has  been  shown  to 
improve tumour localisation and potentially decrease normal tissue irradiation [55]. It 
is therefore an imaging technique that can assist with delineation and an important 
tool in IGRT. 
 
There are multiple commercial hardware and software packages available to perform a 
4DCT.  I  will  describe  the  Varian  Medical  Systems  software  that  was  used  for  this 
research as it is available in both centres where this research was undertaken.  
To create a 4DCT scan, a respiratory trace is recorded throughout the scanning process 
and saved independently. This trace is the anterior-posterior movement of the chest 
wall captured by an infra-red marker box positioned on the xiphesternum. This infra-
red  marker  box  and  its  anterior-posterior  motion  is  an  external  surrogate  of  the 
superior-inferior internal tumour motion. The CT scanner images a 20cm length of the 
thorax for the duration of a respiration cycle and takes 10 consecutive scans over one 
respiration  cycle.  The  bed  then  moves  and  the  next  section  of  lung  is  scanned  in 
exactly the same way. The different scans are divided into 10 “bins” relating to 10 
sequential phases of the respiratory cycle. These are labelled 0%, 10%, …. ,  90%. The 
0% phase usually lies closest to maximum inhalation and maximum exhalation usually 
lies  around  50%.  In  basic  terms  the  respiratory  trace  is  a  sine  wave.  The  clinically 
relevant parameters are the amplitude, which can increase or decrease depending of 
the depth of the patients breath; and the wavelength, which can increase or decrease 
depending on the rate of respiration. The ideal is to have regular breathing both in 
terms  of  wavelength  and  amplitude,  unfortunately  breathing  patterns  are  seldom 
regular in patients with poor pulmonary function, thus there is interest in identifying 
the potential impact of coaching, on image quality and target coverage. There are  
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Figure 3-2. An illustration of the Varian RPM system. - 23 - 
different methods of coaching a patient, for example, audio or visual or a combination 
of  both.  In  addition,  patients  can  undergo  monophasic  or  biphasic  coaching.  During 
monophasic  coaching  only  inspiration  or  expiration  are  prompted  versus  biphasic 
coaching  where  both  inspiration  and  expiration  are  prompted.  There  are  numerous 
papers looking at the benefits of coaching. All forms of coaching are shown to improve 
the regularity of the wavelength and the amplitude of the respiratory trace by varying 
degrees [56]. Whether it is the wavelength or the amplitude that are more consistent is 
important for different reasons.  
During acquisition of the 4DCT planning scan, a consistent wavelength allows a better 
image.  Improving  the  consistency  of  the  amplitude  of  the  respiratory  trace,  is  not 
useful in improving image acquisition. However, if there is abnormally large movement 
amplitude during the recording of the respiratory trace in 4DCT, it may not represent 
the amplitude of tumour motion on treatment. If coaching is introduced during the 
planning scan in order to maintain constant wavelength, in theory coaching would have 
to  happen  during  treatment  in  order  to  maintain  the  coaching  amplitude.  However 
introducing coaching for this theoretical risk, one has to be aware there are concerns 
coaching can increase the tumour amplitude which would translate into larger volumes 
and more toxicity [57]. This study suggested that a coached 4DCT could not be used 
when there is no coaching performed during treatment [54]. However on review of the 
study,  it  reported  a  mean  increase  in  PTV  of  10.2%,  which  from  our  own  work, 
correlates with an increase in V20 of around 1-2%. This increase in V20 is extremely 
unlikely to be clinically relevant. The same paper suggests that there is a different 
centre of mass (COM) for the ITV delineated in coached and free breathing scans. The 
COM varies by a mean of 2.7mm. It is not described in which axes this movement occurs 
nor whether it is primarily in one direction or divided amongst the six directions. It is 
unlikely  motion  of  this  magnitude  would  result  in  any  clinical  consequence.  As  the 
evidence  currently  stands,  there  is  no  evidence  that  coaching  at  4DCT  to  obtain  a 
better image and not coaching on treatment will cause any clinical detriment to the 
patient. 
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It was hoped that coaching during treatment delivery would decrease the variability of 
the tumour amplitude and hence improve target coverage [58]. However the studies 
undertaken demonstrate a reduction in the variability of the external surrogate, not 
the  internal  tumour  movement,  and  these  do  not  necessarily  correlate.  It  remains 
unproven  whether  coaching  reduces  the  variability  of  the  tumour  amplitude. 
Respiratory gated radiotherapy is a different situation. This is when the radiation beam 
is switched on during one phase of the respiratory cycle. As the radiation beam requires 
a regular breathing cycle to switch on and off, a regular wavelength is a paramount 
therefore in respiratory gated radiotherapy, therefore coaching is recommended. 
In summary, although coaching can improve consistency of wavelength and amplitude, 
and hence improve the image acquisition, there are concerns regarding its use and no 
evidence  it  results  in  improved  target  coverage  outcome  other  in  respiratory  gated 
radiotherapy  where  it  is  recommended.  Further  investigation  into  the  benefit  of 
coaching in non-respiratory gated radiotherapy patients is required. 
 
The 4D software is also used to create a Maximum Intensity Projection scan (MIP), an 
Average Intensity Projection (Ave-IP) and a Minimum Intensity Projection (Min IP) from 
the raw data. In these datasets, each pixel is assigned the highest (in the MIP), the 
average (in the Ave-IP) or the lowest (in the Min-IP) density value that occurred, taking 
account of all 10 scan phases. For a solid tumour moving within low density lung tissue, 
the MIP gives a good representation of the volume occupied by the tumour throughout 
the respiratory cycle, while the Ave-IP is the data-set appropriate for calculation as it 
represents  the  lung  volume  in  its  average  position.  Figure  1-4  demonstrates  the 
difference between the different constructed image-sets. 
There is great controversy regarding the best method of delineating from a 4D scan due 
to  abundance  of  data-sets  there  are  to  deal  with.  This  will  be  discussed  further  in 
Chapter 2. 
 
 
 
 - 25 - 
Figure  1-4.  Image  demonstrating  the  different  constructed  image-sets:  (a) 
demonstrates  the  different  “bins”  representing  different  phases  of  the  respiratory 
cycle;  (b)  A  Maximum  Intensity  Projection  (MIP)  which  is  where  the  highest  density 
pixel is selected for the image-set; (c) A Minimum Intensity Projection (Min-IP) which is 
where the lowest density pixel is selected for the image-set; (d) An Average Intensity 
Projection (Ave-IP), where the average density pixel is selected for the image-set 
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In 4DCT the traditional labels of GTV, which is enlarged to CTV, then ITV then PTV are 
no  longer  appropriate.  On  a  4DCT,  there  are  a  number  of  methods  of  delineating 
however the following volumes are commonly created using a 4DCT:  
•  The Gross Internal Tumour Volume (GITV) is the gross tumour in all phases of 
the respiratory cycle. 
•  The Clinical Internal Target Volume (CITV) encompasses the CTV in all phases of 
the respiratory cycle.  
Whether the 5mm margin for microscopic invasion is added before or after the internal 
target  motion  will  vary  depending  on  the  software  available  to  the  clinician,  and 
clinician preference. The final margin applied is the set up margin from CITV to PTV. 
Figure  1-5  demonstrates  the  traditional  labelling  of  structures,  and  the  labelling  of 
structures that will be used when there is discussion of 4DCT. 
 
 
1.3.3 Imaging techniques used in Verification 
 
There are 2 new radiotherapy verification developments in lung cancer.  
1) The first is the development and use of novel image types to allow for easier 
verification  of  structures  and  better  matching.  These  include  kV  imaging, 
fluoroscopy,  CBCT,  and  MV-cine.  Kilovoltage  imaging  and  fluoroscopy  have  been 
traditionally been used in check simulation, but they can now be produced on the 
treatment machine using an imager which is attached to the linear accelerator. 
This treatment machine imager also allows the acquisition of cone-beam CT (CBCT) 
scans.  These  scans  permit  the  3-dimensional  verification  of  the  position  of  the 
tumour and surrounding organs at risk [59]. MV-cine are a number of BEV frames 
captured  using  the  treatment  beam  run  together  to  create  a  cine-image  of  the 
tumour during the treatment delivery [60]. 
2) The second is that there is now hardware and software to allow easy on-line 
image acquisition, review and set-up modification prior to treatment. Images of the 
patient,  taken  using  treatment  machine  imagers  attached  to  the  radiation 
treatment  machines  are  taken  immediately  prior  to  treatment.  These  are  then - 27 - 
reviewed and matched to the planning DRR. Lastly immediately prior to treatment, 
a shift is made so that all systematic and random errors, in their traditional sense, 
are minimised. The patient is then treated.  
 
In  the  current  era  of  lung  oncology,  potential  errors  cannot  be  easily  explained  or 
understood  using  the  traditional  description  of  systematic  and  random  errors,  as 
explained above. Delivery errors are better divided into 4 categories which can have 
systematic  or  random  components.  They  have  been  divided  in  this  way  so  that  the 
different imaging techniques, suitable for each error, can be discussed individually. - 28 - 
Figure 1-5. The image on the left demonstrates the terms dictated by ICRU 50 / 62 that 
are commonly used. The image on the right demonstrates the terms that will be used 
when discussing volumes delineated using a 4DCT. 
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1.  Interfraction Patient Motion (set-up error) 
Because immobilisation is imperfect, the patient will lie in a slightly different position 
every day. If this varies day to day during treatment, this is a random error whereas, if 
the patient lies in a consistently different position during planning and treatment this 
would result in a systematic error. More difficult to classify is if the patient begins to 
relax into the bed over the course of 4 weeks of radiation resulting in a consistently 
posterior set-up, this is probably best clarified as a newly acquired systematic error. 
Daily online matches to minimise interfraction patient set up error could be done with:  
1) A pre-verification MV iso-image, as discussed above, which delivers an additional 
dose of 4mSv. 
2) A CBCT which delivers a dose of 45mSv. 
3) A pair of static orthogonal kV images which deliver only 0.2mSv.  
The  newly  acquired  image  can  then  be  initially  automatically  matched  using  stable 
bony anatomy, such as the spine, to the planning DRR and then manually verified. The 
shift required to have the patient in the planning scan position is highlighted in the 
control  room  and  when  approved,  the  shift  is  made  to  the  treatment  bed.  All 
corrections  are  limited  by  the  image  quality  and  the  ability  of  the  operator  to 
perform/confirm the match. Figure 1-6 demonstrates a CBCT image and a pair of kV 
orthogonal images. Figure 1-3 is an example of MV images. 
Prior  to  the  introduction  of  treatment  machine  imagers,  if  on-line  matching  was 
required, MV images were traditionally used as it was only possible to create MV images 
using the LinAC. However MV radiation is absorbed via the Compton Effect and the 
uniform absorption makes it difficult to differentiate the stable bony structures such as 
the spine from the soft tissues. The harder it is to pick out the stable bony structures, 
the more difficult either an automatic or manual match is to make. There are now good 
comparative studies of MV images versus both CBCT and kV orthogonal images for set-
up.  These  have  consistently  demonstrated  inferiority  of  MV  images  and  hence  MV 
images do not have a role in interfraction patient motion [61]. 
When comparing kV orthogonal images to CBCT for on-line set up, they were found to 
be equally as good at matching to DRR in all planes, however correction of rotational 
errors remains superior with CBCT [62]. Rotational errors cannot be adjusted for on the - 30 - 
treatment unit, so if a rotational error of >2-5 degrees is noted, the patient would be 
repositioned and a further on-line image taken. As a result, other than with rotation 
that cannot be adjusted for, CBCT and kV orthogonal images are equally as good for 
reducing  interfraction  patient  motion  or  set  up.  Due  to  the  radiation  dose  of  kV 
orthogonal imaging being lower, kV orthogonal images should be used for daily on-line 
set up as it delivers far less dose.  
 
Daily on-line set up with kV images minimises the systematic and random errors present 
due to changed patient position, however many departments cannot image daily due to 
time constraints. Different imaging protocols include: on-line imaging daily for the 1st 5 
days only, online imaging days 1-5 then weekly, online imaging weekly or on alternate 
days. An off-line protocol must then be implemented for the days that on-line imaging 
does not take place. An off-line protocol will reduce the systematic error however the 
random error will only be minimised the days an on-line image is performed. There is 
no  consensus  on  which  of  these  protocols  is  the  best  in  reducing  systematic  set-up 
error.  Higgins  et  al.  recently  published  a  paper  comparing  these  off-line  protocols. 
They  compared  daily  online  imaging,  imaging  the  first  5  days,  imaging  weekly  and 
imaging  alternate  days.  They  confirmed  that  daily  online  set-up  can  allow  set  up 
margins  of  3-4mm  and  significantly  reduces  random  set-up.  Of  the  other  imaging 
protocols, which only dealt with systematic error and do not make any difference to 
random  error,  an  average  of  the  1st  5  days  had  unfavourable  levels  of  geometric 
uncertainty  in  comparison  to  the  weekly  or  alternate  days  protocol,  which  reduced 
systematic errors so that a set-up margin of 5mm could be used [63]. Further research 
is required to confirm the best imaging protocol. 
 
In  summary,  kV  orthogonal  images  are  most  suitable  imaging  technique  for  the 
interfraction  patient  motion  error.  As  they  deliver  minimal  radiation  exposure  it  is 
possible  to  undertake  online  daily  imaging  which  is  effective  at  minimising  both 
systematic and random set-up error. 
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2.  Interfraction Tumour Motion (tumour migration and volume change) 
Tumour migration and volume change during the course of 4-6 weeks of radiation is a 
recognised phenomenon. This migration can be an increase in the volume, a decrease 
in the volume or a migration of the centre of mass as a result of many factors for 
example  weight  loss,  inflammation  or  re-expansion  of  a  lung.  In  terms  of  tumour 
migration:  Sonke  et  al.  report  that  the  mean  interfraction  tumour  migration  of  the 
volumes was 1.6mm (left-right), 3.9mm (cranio-caudal) and 2.8mm (anterior/posterior) 
[64]; Britton et al. results were not too dissimilar with migration of the tumour volume 
reported as 3mm (left-right), 5.4mm (cranio-caudal) and 4.5mm (anterior/ posterior) 
[65]. In terms of changes in tumour volume: Erridge et al. showed that in a population 
of 25 patients, tumour shrinkage of at least 20% occurred in 40% of the patients [66]; in 
Britton et al volume loss of at least 40% occurred in 50% of the patients; Bosmans et al 
report a 30% reduction in 13% of patients and a >30% increase in tumour size in 17% of 
patients  [67].  There  are  other  reports  of  volumes  increasing  over  the  course  of 
radiotherapy, Underberg et al. reported an initial increase in tumour volume of 10cm3 
in at least 2 of 40 patients [68], however the incidence of increase in tumour volume 
does appear to be less than the incidence of tumour volume reduction. 
Another form of interfraction tumour motion is baseline shifts where end-inspiration 
and end-expiration position varies. Sonke et al. reported the largest study looking at 
this specific error in 56 patients. They found the systematic average baseline variations 
were 1.6, 3.9, 2.8mm and the random baseline variations 1.2, 2.4, 2.2mm in left-right, 
craniocaudal and anterior-posterior directions respectively [69]. The baseline shift is a 
difficult  error  to  visualise  and  therefore  monitor.  As  a  result  of  this,  Sonke  et  al. 
developed the 4D-CBCT, which is an online image which gives all the information of a 
CBCT  with  additional  information  on  baseline  shift  and  intrafraction  tumour  motion 
(respiration motion) [70]. It is currently unknown whether baseline shifts in an external 
structures correlate with baseline shifts in the internal tumour and this requires more 
investigation. This error becomes of more significance in respiratory gated radiotherapy 
where the aim is to irradiate in either end-expiration or end-inspiration. 
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Figure 1-6. (a) Three slices through a CBCT with the planning GTV superimposed, (b) A 
pair of orthogonal kV images with the structures from the planning DRR superimposed. 
 
(b)  
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Each of these potential interfraction tumour motion errors can only be highlighted by 
CBCT. CBCT allows visualisation of the tumour bulk, and therefore enable a check to 
ensure there has not been significant alteration the tumour bulk or position from the 
planning  scan.  If  either  has  occurred,  the  patient  requires  re-planning  to  prevent 
geographical miss. CBCT is the only imaging technique that gives an accurate position 
and  size  of  the  tumour  and  therefore  should  be  incorporated  into  all  verification 
protocols  to  check  for  interfraction  tumour  motion  error.  There  is  no  evidence 
supporting daily imaging to identify interfraction tumour, the feeling is that CBCT can 
be used once or twice a week to identify any concerns however the ideal frequency of 
CBCT requires further investigation. A number of groups have suggested that in Stage I 
tumours doing a soft tissue match onto the tumour would reduce the errors that occur 
due to tumour migration [71,72], however on the other hand, in node-positive tumours, 
there are concerns that soft-tissue matching contribute further errors and hence are 
best avoided [73].  
 
Using CBCT to identify patients where the tumour volume has altered or moved has 
raised the possibility of adaptive planning, i.e. altering the volume or plan to allow for 
these changes. Britton et al. repeated 4DCT planning scans on 10 patients undergoing 
radiotherapy and found that when the original plan was recalculated on the repeat 
4DCT’s,  as  a  result  of  changes  in  tumour  volume,  mobility  and  patient  set-up, 
occasionally  there  were  dramatic  dosimetric  consequences  [74].  There  has  been 
enthusiasm in some areas for reducing volumes in those patients whose tumours have 
shrunk, in order to spare normal lung by reducing the V20 during the radiation [75] 
however,  there  are  some  widely  felt  concerns  regarding  this.  The  reluctance  to 
embrace this technique is because it has been shown that non-small cell lung cancer 
stem cells are radioresistent [76] and although the tumour bulk may have reduced, 
there may be a small number of radioresistant stem cells that cannot be visualised by 
the repeat imaging. By reducing the volume, these radioresistant cells may lie, unseen, 
outside the new gross tumour volume. By irradiating the most resistant cells to a lesser 
dose  you  increase  the  likelihood  of  local  relapse.  Consequently,  replanning  due  to 
marked increase or migration of tumour volume, or patient set-up or body habitus may - 34 - 
reduce toxicity in the minority of patients who would suffer dosimetric consequences 
due to these events [70]. However adaptive planning following tumour shrinkage should 
be used with caution and only within clinical trials.  
 
In summary, in node-positive tumours, once or twice weekly online CBCT with a bony 
match,  can  be  used  in  to  highlight  those  patients  who  have  suffered  a  significant 
increase in tumour size, or tumour migration, so that a repeat 4DCT can occur for re-
planning.  If  the  tumour  reduces  in  size,  replanning  would  not  be  advised  in  these 
patients. In Stage I patients, online CBCT can be used for a soft tissue match.  
 
3.  Intrafraction patient motion (patient moving during treatment) 
While  the  patient  lies  on  the  treatment  bed,  there  is  some  intrafraction  patient 
movement. The intrafraction patient motion increases as the treatment time increases. 
Purdie et al suggested that any treatment taking more than 30 mins would require a 
further  on-line  image  because  after  34  mins,  the  intrafraction  tumour  position 
deviations changed from being 2.2mm, which was considered acceptable due to their 
3mm action level, to >11mm which was considered unacceptable [68]. Hoogeman et al 
reported that the standard deviation (SD) of the intrafraction displacements increased 
linearly over time. The SD increased to 0.8, 1.2, 2.2mm respectively in a period of 15 
mins [77]. As margins are getting smaller and especially in very conformal treatment 
such  as  stereotactic  radiotherapy,  these  small  errors  become  more  important  to 
quantify to ensure target coverage. 
 
4.  Intrafraction tumour motion (respiration-induced tumour motion) 
This is primarily the respiration-induced tumour motion during the radiation treatment. 
There  is  also  a  degree  of  intrafraction  motion  as  a  result  of  hysteresis  and  heart 
motion. Hysteresis is difference between the inhalation and exhalation trajectory of 
the tumour [78]. The challenge with intrafraction tumour motion is that it can vary 
from day to day, week to week. A single assessment of intrafraction motion is captured 
in a “snap-shot” 4DCT scan. This is described as a “snap-shot” because although 4DCT 
gives the additional dimension of time, the period of time it takes to scan the primary - 35 - 
tumour with motion is only for the duration of one respiratory cycle. However what is 
imaged on the 4DCT at simulation may or may not be the same respiration-induced 
movement and hysteresis that occurs during treatment. If the average movement and 
hysteresis is captured during the planning, and during any fraction of treatment there is 
slightly more or less movement than the average, this would be considered a random 
error and it is unknown if this would have clinical consequences. If during the 4DCT 
planning scan there is less or more tumour motion visualised than normal, the margin 
will consequently be either too big or too small, resulting in a systematic error. As a 
result the target would be consistently missed or normal tissue consistently irradiated, 
which is more likely to have a clinical consequence. There are a number of techniques 
that can be used to ensure that what is visualised during the CT planning scan is what is 
occurring on the treatment room.  
1) Abdominal compression is designed to reduce the respiration induced motion so 
that  it  is  kept  at  a  minimum  both  during  planning  and  subsequently  during 
treatment. This compresses the abdomen, reducing the tidal volume and hence the 
intrafraction  tumour  motion  [79,80].  However,  the  American  Society  for 
Therapeutic Radiology and Oncology state as a pre-requisite to immobilization in 
SBRT  patients,  that  patients  need  to  be  able  to  lie  comfortably  despite  their 
immobilization technique. It is recognised that patients feel less comfort with an 
abdominal compression frame in place. In addition, a recent paper has confirmed 
that although abdominal compression reduces motion, it increases the variation in 
the  intrafraction  tumour  motion  and  therefore  is  not  as  suitable  a  method  of 
managing intrafraction patient motion as previously thought [81].  
2) CT scans undertaken during breath-hold have been mentioned in the literature 
[82]. This is used mainly in centres without 4DCT with the aim of capturing tumour 
in  a  stable  position  (a  specific  respiratory  “gate”).  This  allows  planning  and 
treatment during breath hold with the aim of irradiating while the tumour is not 
moving thus removing the uncertainty of a population based margin or potentially 
decreasing  the  normal  tissue  irradiation.  However  as  we  have  a  4DCT,  the 
reproducibility of a breath-held CT on treatment is subject to a great deal of error - 36 - 
[83] and we have a population with significant co-morbidity who are not likely to 
tolerate breath hold, this is not something we plan to investigate.  
3) The use of a single “snap-shot” 4DCT can produce random or systematic errors if 
the intra-fraction motion during treatment is different to that visualised at 4DCT 
planning. There are a number of papers that look at the likelihood of a systematic 
intrafraction  tumour  motion  error.  Michalski  et  al.  reported  tumour  motion 
reproducibility of 87% and suggested rechecking the intrafraction tumour motion at 
some point after 4DCT to highlight the small proportion who had different amounts 
of  movement  [84],  Bosmans  et  al.  reported  that  although  a  small  number  of 
changes in tumour motion were seen over the course of treatment, in only 4% of 
patients  this  would  have  resulted  in  an  increase  of  the  internal  margin  [63], 
Guckenberger et al. found that the mean peak to peak tumour motion changed by 
only  0.9mm  on  two  different  scans  [85],  Sonke  et  al.  reported  that  the  mean 
variability of the tumour trajectory shape did not exceed 1mm (1 SD) [60]. These 
papers suggest that for the vast majority of patients it is safe to perform one 4DCT 
planning scan and treat without re-imaging the intrafraction motion. To identify 
the  few  patients  who  have  a  systematic  error  can  be  done  by  re-imaging  the 
intrafraction  tumour  motion  either  prior  to  or  during  the  first  few  fractions  of 
treatment. 
4)  Fluoroscopy  can  be  used  to  make  a  further  assessment  of  the  intra-fraction 
respiration induced motion; however tumours are not always seen on kV images. 
Fiducials can be implanted into the tumour percutaneously or transbronchially so 
that the intrafraction motion can be monitored easily on kV fluoroscopy. However 
this is not commonly performed, as insertion can be technically difficult, there is a 
significant  risk  of  pneumothorax  [86]  and  there  are  high  drop-out  rates  after 
bronchoscopic placement [87]. 
5) Due to the fact a CBCT image is taken over a number of respiratory cycles, it 
gives a picture of the tumour over a number of respiratory cycles i.e. it gives an 
impression of intrafraction tumour motion. The CBCT image has the high density 
tumour in the average position of the tumour, however there is varying degrees of 
density around it that can be used to either subjectively assess the tumour motion - 37 - 
when comparing the image to the Ave-IP, or objectively quantify tumour motion 
using the complicated published technique [88]. This is a quick, subjective method 
that can be used to ensure the tumour motion does not differ widely from what was 
captured at 4DCT. 
6) 4D-CBCT’s allows online visualisation of intrafraction tumour motion [90]. Sonke 
et al. found that in Stage I tumours, the systematic intrafraction motion variability 
was  1.2,  1.2  and  1.8mm  and  the  random  variation  was  1.3,  1.5  and  1.8mm 
(random)  in  left-right,  craniocaudal  and  anterioposterior  direction  respectively 
[66]. These measurements confirm that in the majority of patients there is minimal 
variation  in  intrafraction  tumour  motion,  however  the  4D-CBCT  offers  an 
opportunity  to  identify  any  outliers  with  more  variation  which  may  result  in 
geographical miss. 
7) Many 4DCT planning scans require an external surrogate to be placed on the 
xiphisternum  or  the  abdomen  in  order  to  create  the  scan.  Amplitude  Monitored 
Treatment  Delivery  (AMTD)  is  a  novel  technique  developed  in  the  VU  Medical 
Centre,  Amsterdam  which  uses  the  respiratory  trace  created  using  the  external 
surrogate, as a surrogate for the internal tumour. AMTD is achieved by noting the 
maximum  amplitude  of  the  external  surrogate  cranio-caudal  motion  during  the 
4DCT scan as an estimation of the maximum intrafraction tumour motion. If the 
external  surrogate  cranio-caudal  motion  exceeds  this  threshold,  the  treatment 
machine is programmed to automatically turn off. The problem with this technique 
is that internal structures do not necessarily correlate with external surrogates. 
Correlation  coefficients  between  tumour  and  external  surrogate  have  been 
reported  as  87%  in  the  superior-inferior  direction,  but  as  little  as  44%  in  the 
anterior-posterior position by Koch et al. [89] and 81% in all directions by Hoisak et 
al. [ 90].  The  lack  of  correlation  was  also  confirmed  by  a  study  examining  the 
residual  movement  within  one  respiratory  bin  over  a  course  of  treatment  and 
identified it to be as much as 6.2mm [91]. Implementing AMTD is a lengthy process, 
and  as  the  machine  is  turned  on  and  off  treatment  can  take  longer  to  deliver, 
increasing the intrafraction patient movement and potential consequent  errors. - 38 - 
AMTD may offer assistance with target coverage that is otherwise missed due to 
intrafraction tumour motion, however this requires further investigation.  
 
 
1.3.4 Different treatment delivery techniques available as a result of IGRT 
 
1.3.4.1 Phase-Based and Amplitude-Based Respiratory Gated Radiotherapy 
With the introduction of 4DCT, there has been a great deal of interest regarding the 
possibility of using the 4DCT to plan and deliver respiration gated radiotherapy (RGRT). 
This involves treatment delivery at selected phases of the respiratory cycle which can 
be  achieved  using  different  systems.  Within  our  institution,  the  Varian  RPM  system 
(RPM; Varian Medical Systems, Palo Alto, CA) is used. The patient’s respiration cycle is 
monitored continuously by an external surrogate; an infrared marker box placed on the 
xiphisternum.  The  movement  of  the  marker  box  is  picked  up  by  a  camera  and  a 
respiratory trace observed in the control room. This trace enables the selection of a 
respiratory phase or “gate” for treatment delivery and the treatment beam is switched 
on only during this interval. RGRT can be delivered in end-inspiration or end-expiration. 
There are two methods of RGRT, phase-based gating and amplitude based gating, each 
with  advantages  and  limitations.  Figure  1-7  illustrates  phase-based  and  amplitude-
based RGRT. 
 
In Phase-based RGRT, the breathing cycle is divided into multiple time segments and 
radiation delivery is based on the same phase of the patient's respiratory cycle. The 
phases  selected  for  irradiation  are  usually  90%,  0%,  10%  or  40%,  50%,  60%  in  end-
inspiration and end-expiration respectively. The main limitation of phase-gated RGRT is 
while  there  may  be  no  baseline  shift  in  the  external  surrogate  baseline  position; 
internally  there  may  be  a  baseline  shift.  There  is  no  information  available  as  to 
whether or not there is any correlation between the external surrogate baseline shift 
and  the  internal  tumour  baseline  shift.  Hence  the  tumour  position  during  the  end-
inspiration or end-expiration may differ from that  captured on the 4DCT planning scan. 
Although  the  treatment  beam  is  on  at  the  correct  time,  end-inspiration  or  end-- 39 - 
expiration,  the  tumour  position  at  this  time  could  be  different  to  that  seen  during 
planning.  A further possible problem is the potential for a phase-shift between the 
external  surrogate  and  the  internal  tumour.  This  would  result  in  the  extremes  of 
motion  of  the  tumour  not  coinciding  with  the  extremes  of  position  of  the  external 
surrogate.  If  this  has  occurred  in  the  planning  scan  and  continues  throughout 
treatment, it is consistent so consequently will irradiate in the correct area. If a phase-
shift occurs during treatment, but was not present at planning, in the beam would be 
switched on at the incorrect time. Spoelstra et al. used static MV images taken during 
RGRT  treatment,  during  treatment  at  end-inspiration,  to  calculate  the  standard 
deviations of systematic ( ∑ )  and random ( σ ) errors in tumour position and found 
them to be 1.8mm and 1.7mm respectively [92]. This study reassures us that baseline 
shifts and phase shifts are usually limited. The study also offers a quick verification 
method to ensure the tumour is in the field by taking an MV image.  
In amplitude-based gating, treatment delivery is based on the absolute position of the 
marker  block  on  the  patient's  thorax  or  abdomen,  regardless  of  the  phases  in  the 
patient's respiratory cycle. The limitation of amplitude-based RGRT is that if there is a 
baseline shift in the respiratory trace, and this does not correlate with a baseline shift 
in tumour position, the treatment beam will be switched on when the tumour is not in 
end-inspiration or end-expiration. Although there are studies looking at the dosimetric 
consequences of amplitude-based gating [93,94] there are no studies similar to the one 
mentioned above, confirming the residual motion within the treatment “gate”. 
RGRT has been shown to reduce the size of the PTV when compared to the standard 4D 
PTV [95], and there are some reports that toxicity parameters are reduced [96,97] with 
the use of RGRT although whether this represents a difference in clinical outcome and 
requires further investigation. 
 
There are further concerns regarding both forms of RGRT.  
1.  One source of geometric uncertainty is the correlation between internal tumour 
motion and movement of the external surrogate when using the Varian RPM system, 
as occasionally it can be inconsistent [98]. Despite the Spoestra et al. confirming - 40 - 
minimal  systematic  and  random  residual  motion,  unease  regarding  disparities 
between external surrogate and internal tumour position remains.   
2.  Respiratory  coaching  is  advised  for  RGRT.  It  is  more  important  to  reduce 
baseline shifts in RGRT and coaching has been shown to do this. In addition, the 
treatment beam requires a regular wavelength in the respiratory cycle to turn on. 
Coaching, especially auditory, increases the regularity of the wavelength therefore 
it is advised [99,100].  
3.  A  further  disadvantage  of  RGRT  is  that  due  to  irradiation  only  proceeding 
during  a  specific  respiratory  ‘gate’  or  ‘phase’,  the  radiotherapy  beam  spends 
around  80%  of  the  respiration  cycle  switched  off.  Treatment  delivery  therefore 
takes longer which can in turn increase the risk of shifts in patient position [68].  
4.  As well as in continuous (non-gated) 4DCT treatment as discussed above, the 
use of a single 4DCT planning scan, for RGRT can also result in systematic errors in 
the treatment plan, and random errors during treatment when what is visualized on 
the planning 4DCT is not representative of intrafraction motion during treatment 
[101].  
5.  There  remains  differing  ideas  regarding  whether  the  selected  phase  of 
respiration  should  lie  in  end-inspiration  or  end-expiration  [102].  End-inspiration 
captures the lung at maximum expansion therefore potentially sparing more normal 
lung tissue [103] however the tumour remains in end-inspiration for significantly 
less  time  therefore  there  is  a  smaller  treatment  window  [104]  and  the  end-
inspiration  tumour  position  is  more  variable  than  the  end-expiration  tumour 
position.  In  end-expiration,  there  is  a  longer  treatment  window,  the  tumour 
position is more stable, but the lung is compressed therefore more lung is within 
the treatment field. 
6.  There  also  remains  controversy  concerning  the  threshold  of  craniocaudal 
tumour  motion  when  RGRT  should  be  considered.  The  AAPM  recommended 
respiratory management for tumour movement greater than 5mm [105], Spoelstra 
et al. used 7.5mm, Starckschall et al. investigated if tumour motion could be used 
to predict those patients who would have the most clinical benefit however, they - 41 - 
only found a correlation between tumour motion and clinical benefit with RGRT in 
small tumours (GTV <100cm
3, [91]). 
The theoretical advantages of RGRT are: reduction in toxicity; potential for dose 
escalation;  and  fewer  patients  having  radical  treatment  withheld  on  account  of 
large volumes or unacceptable toxicity parameters. It is an interesting concept; 
however the clinical benefit remains to be seen.  
 
 
 - 42 - 
Figure 1-7. Illustration demonstrating the different forms of respiratory gated 
radiotherapy. 
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1.3.4.2 Stereotactic Radiotherapy 
Stereotactic  body  radiation  therapy  (SBRT)  is  a  newly  emerging  radiotherapy 
treatment, aimed to deliver a high dose of radiation to the tumour, a biological dose 
equivalent of around 180Gy, utilizing either a single dose or a small number of fractions 
with a high degree of precision [106].  
A combination of factors enables SBRT to deliver these large doses to the tumour. One 
such factor is to keep the planned target volume as small as possible, which is achieved 
by only treating tumours of <50mm in diameter and using very small, 3-5mm GTV to 
PTV  margins.  Another  factor  enabling  the  delivery  of  such  high  doses  is  the  use  of 
multiple fixed beams, usually 10-12 coplanar beams, with a linear accelerator so that 
the incidental dose to organs at risk in the beam projectory are not unacceptably high. 
The large numbers of beams make the isodose lines very conformal to the PTV and also 
results in very steep fall off dose gradients.  The combination of a requirement of small 
margins  and  the  steep  fall  off  dose  gradients  require  the  high  degree  of  precision 
required in SBRT. This precision is achieved by the use of IGRT. Due to the minimal 
margins  and  high  doses,  SBRT  requires  much  more  stringent  constraints  and 
minimisation of the effects of potential geometrical errors, with appropriate audit and 
QA. An awareness and calculation of the four errors discussed in detail in section 1.3.3. 
There is no fool-proof method for infallible management or prevention or of any of the 
four  errors.  They  are  potential  errors  that  can  be  managed  adequately  with  the 
techniques discussed below. Once a centre has decided how they hope to managed 
these errors and SBRT has been implemented, they must evaluate and audit their errors 
to ensure their method is adequate. 
1) Methods to Manage Intrafraction Tumour Motion 
These  are  discussed  in  more  detail  in  section  1.3.3.  All  of  these  methods  have 
limitations but used in combination, consistent local control rates of >90%, confirm 
that these are adequate.   
•  There was a great deal of interest in the Stereotactic Body Frame (Elekta 
Oncology Systems, Crawley, UK) that allows abdominal compression which 
has been proven to reduce intrafraction tumour motion. However a recent 
paper has demonstrated that the Stereotactic Body Frame with abdominal - 44 - 
compression can increase the variability in the intrafraction tumour motion 
and  therefore  this  may  not  be  as  suitable  a  method  of  managing  intra-
fraction patient motion as previously thought [76]. 
•  A 4DCT to assess the normal intrafraction tumour motion and encompass 
the movement in its entirety. 
•  CBCT  or  4D-CBCT  during  online  set  up,  where  the  intrafraction  tumour 
motion can be assessed and the plan changed or adjusted only if the motion 
is different from what was seen at planning.  
•  The RPM system which can be used to monitor the external marker as a 
surrogate of intrafraction tumour motion so that the treatment beam can 
be  stopped  if  the  surrogate  demonstrates  different  motion  than  seen  at 
planning.    As  discussed  above,  the  correlation  is  not  always  consistent; 
however this may be used in combination with other methods. 
 
2) Methods to Manage Interfraction Tumour Motion  
This motion is limited because a treatment course lasts no more than two weeks 
and tumours are less likely to migrate over this period of time. In SBRT, the CBCT 
that is used for set up is matched to tumour, rather than bone, so unless there has 
been  a  large  change  in  position,  so  much  so  that  the  dosimetry  is  likely  to  be 
different, a tumour match will usually remove any error relating to interfraction 
tumour  motion.  If  the  tumour  has  increased  in  size  between  planning  and  any 
fraction, the patient will undoubtedly require re-planning to prevent under-dosing 
areas of the periphery of the tumour.  
3) Methods to Manage Intrafraction Patient Motion 
Increased  treatment  times  result  in  increased  intrafraction  patient  motion. 
Hoogeman  et  al.  demonstrated  that  the  SD  of  the  intrafraction  patient  motion 
increased in 15 minute intervals from 0.8mm to 1.2mm to 2.2mm [73]. Purdie et al. 
confirmed this relationship by showing that the mean intrafraction patient motion 
increased from 2.2mm to 5.3mm when the treatment took over 34mins [68]. As a 
result of these studies, during SBRT where the patients are immobilized as they are 
in  standard  conformal  radical  radiotherapy,  with  the  thoracic  board  and  knee - 45 - 
support which is described as “frameless” SBRT, the CBCT should be repeated every 
30 minutes. As treatments take on average 45 minutes, after about 25 minutes of 
treatment it should be paused in order to acquire a further CBCT. With this CBCT a 
further online set up with shift is performed prior to continuing the treatment. 
There are some other tools produced by different manufacturers to limit this error 
which  can  be  used.  The  ExacTrac  System  (BrainLAB,  Germany)  continuously 
monitors around six infrared markers on the patient’s chest wall during treatment, 
and  cuts  off  the  radiation  beam  if  the  markers  move  outwith  the  movement 
encompassed  in  the  margin.  This  is  thought  to  reduce  the  intrafraction  patient 
motion,  but  at  the  expense  of  prolonging  treatment.  The  second  tool  produced 
with  an  aim  of  reducing  intrafraction  patient  motion  was  the  Stereotactic  Body 
Frame, but as discussed above reduces intrafraction tumour motion at the cost of 
increased variability. Therefore other methods which do not increase variation are 
preferable.  
4) Methods to Manage Interfraction Patient Motion 
Patient set up is of prime importance in SBRT in order to maintain the small GTV to 
PTV  margins  that  are  required.  CBCT  matching  to  tumour  rather  than  to  bony 
anatomy  is  required  in  all  cases  of  SBRT.  There  has  been  a  plethora  of  papers 
discussing the use of CBCT for tumour matching in SBRT and all have suggested that 
the remaining systematic errors are all within the 3-5mm margin applied [107,108].  
 
There were three original Phase II trials of SBRT in early-stage medically inoperable 
NSCLC  patients  [12,13,14].  Since  their  publication  SBRT  has  been  implemented 
worldwide and there are now numerous Phase II trials reported. All three seminal trials 
used slightly different techniques. Timmerman et al. used abdominal compression with 
a Stereotactic Body Frame with the theoretical view at the time that this would reduce 
intrafraction  tumour  motion  and  intrafraction  patient  motion.  To  limit  interfraction 
patient motion and interfraction tumour motion, this group used CBCT. Senan et al. 
used  4DCT  for  assessing  and  incorporating  intrafraction  tumour  motion,  CBCT  for 
interfraction  tumour  and  interfraction  patient  motion  and  the  Exactrac  system - 46 - 
intrafraction patient motion. The Japanese trial was a combination of many different 
immobilization and verification techniques.  
The doses used in the three papers also differ, which may have resulted in the slightly 
different toxicity outcomes. Timmerman et al. used 60-66Gy in 3 fractions, Senan et al. 
used a variety of fractionation regimens depending on the likelihood of toxicity, but 
both of these papers had a biological effective dose of up to 180Gy. The Japanese 
paper used a wide range of doses (range 57Gy - 180 Gy) and found that there was a 
statistically  significant  outcome  if  doses  were  >100  Gy.  As  there  is  now  significant 
literature on the tolerance and quality of life after a biological effective dose of around 
180 Gy, this is usually what is used.  
Despite different techniques, the outcomes in the three trials are similar. Timmerman 
recently published extended follow up of his prospective Phase II trial quoting 2-year 
local control rates of 95%. The Senan group had a median follow up of 12 months and 
reported a local control rate of 93%. Onishi et al. had a median follow up of 24 months 
and  showed  a  local  control  rate  of  92.9%,  3-year  lung  cancer  specific  survival  was 
88.4%. These outcome data are so good that there is a division in the radiation oncology 
community as to the next step. Some feel a Phase III randomised controlled trial of 
SBRT  versus  standard  conformal  radiotherapy  is  required  and  there  is  such  a  trial 
ongoing in Scandinavia, a similar trial from the Netherlands had to close due to poor 
accrual therefore it is unknown whether a trial of this nature will ever be successful. 
The other group feel the outcomes are comparable to those of surgery (outcomes of 
which  are  discussed  in  section  1.1.4)  and  Phase  III  randomised  controlled  trials  of 
surgical resection versus SBRT are underway. Unfortunately the UK is lagging behind 
and certain centres have only just begun to implement SBRT into clinical practice.  
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1.4 Aims 
 
The hypothesis of this work was whether IGRT could be safely implemented for clinical 
use in a busy oncology centre. The Beatson, West of Scotland Cancer Centre, as many 
centres in the UK are extremely busy and any development must be safe, of proven 
clinical benefit and optimised to minimise additional resource. The projects undertaken 
were to ensure that the implementation of IGRT fulfilled these criteria. It was also 
important  to  address  issues  that  were  of  use  to  the  wider  wider  international 
radiotherapy community’s knowledge on IGRT in lung cancer.  
The calculation of set-up errors at our centre, to facilitate all further investigation into 
IGRT is obviously the first step in this thesis. This was required to ensure the safety of 
any IGRT process. With a view to implementing 4DCT, there was an obvious paucity of 
papers discussing how to define the target in node-positive patients, so further work 
was required prior to use of 4DCT to ensure the method suggested of using the MIP 
image  was  safe.  MV-cine  offer  a  simple,  method  of  verification,  without  additional 
radiation exposure, that is available to on all modern LinAcs and therefore of interest 
due to the safety and lack of impact on resource. Investigation into whether these fulfil 
a role in radiotherapy verification is of interest. AMTD is a topic that many centres 
around the UK have discussed implementing, and the VUMC have already implemented 
however, further studies are required to assess the robustness of this technique.   
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2. THE CALCULATION OF AN SITE SPECIFIC MARGIN FROM INTERNAL TARGET VOLUME 
(ITV) TO PLANNED TARGET VOLUME (PTV) 
 
 
2.1 Introduction 
 
Currently  in  The  Beatson  West  of  Scotland  Cancer  Centre,  as  discussed  in  the 
introduction during 3-D CT based radiotherapy of lung cancer, a combined margin from 
GTV to PTV of 15mm anteriorly, posteriorly and in both directions laterally and 20mm 
superiorly and inferiorly is used. This margin is to encompass microscopic disease, a 
population based margin for intra-fraction respiration induced tumour motion, and the 
set-up margin from ITV to PTV as suggested by the ICRU guidelines [19,20]. However, 
only the GTV to CTV margin for microscopic disease is quantified. Although Giraud et 
al. quantified a microscopic margin of 6-8mm, when this is used in combination with 
other margins in clinical practise, 5mm is most commonly used. As discussed in section 
1.2.5, margins are not added linearly and it is up to the local centre how to combine 
the different margins. The general consensus worldwide is that when in combination 
with other margins, this margin should be 5mm. Neither the population based margin 
for intra-fraction respiratory induced tumour motion nor the set-up margin from ITV to 
PTV have ever been quantified in our centre. As a result, the amount of the combined 
margin that is allocated to each specific margin is unknown. 
 
There  are  three  main  reasons  why  calculating  the  ITV  to  PTV  set-up  error  is  vital, 
especially in any study of IGRT. 
1) Even without the study of IGRT, set-up errors vary from centre to centre. The 
verification techniques differ in the types of images used, how they are acquired 
and analysed, and the acceptance thresholds. . As a result set-up errors should be 
calculated on a centre-specific basis so that they are accurate and they are neither 
too  small  resulting  in  geographical  miss,  nor  too  big  resulting  in  unnecessary 
irradiation of normal tissue.  - 49 - 
2) As discussed above, one of the imaging technologies used in IGRT is 4DCT for  
planning, which allows the intrafraction respiration-induced tumour motion to be 
visualised so that the margin for this motion can be individualised. In 4DCT scans, 
the volumes delineated begin with GITV, which is grown to CITV for microscopic 
disease  followed  by  a  further  margin  for  set-up  error  to  create  the  PTV,  as 
discussed  in  section  1.3.2.  If  the  set-up  margin  from  CITV  to  PTV  is  currently 
unknown, this needs to be calculated so that once a GITV has been delineated on a 
4DCT scan, and the 5mm has been added for microscopic disease, an accurate set-
up margin can be added to create the PTV.  
3) As a result of different verification protocols and the corrections applied, the 
set-up error varies between centres. Online imaging with CBCT and kV imaging can 
be  used  to  minimise  the  set-up  error  so  that  target  coverage  is  improved  and 
margins  can  potentially  be  reduced  to  spare  more  normal  tissue.  In  order  to 
implement CBCT and kV imaging, and to confirm these new imaging technologies 
are reducing the set-up errors from our current practice, it is necessary to estimate 
a baseline set-up error using our current off-line verification technique. 
 
There are two margin recipes that are used widely. McKenzie et al. wrote extensively 
in  a  British  Institute  of  Radiology  publication  on  how  to  calculate  the  standard 
deviation of the systematic and random set up errors from iso-images. He derived an 
equation to calculate the set-up margin [23]. Van Herk et al. also published a margin 
recipe [22]. The McKenzie paper was used to calculated the standard deviation of the 
systematic and random errors in our department, and then used both the McKenzie and 
van Herk margin equations to calculate our site specific CITV to PTV margin. 
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2.2 Method 
 
•  McKenzie Publication 
 
McKenzie discusses two aspects of the margin he has published. The first stage called 
the “treatment preparation” is to determine a volume large enough to contain the CTV 
in the majority of cases so that the defined volume will encompass the mean position in 
90% of cases. This stage of delineation is primarily concerned with the intra-fraction 
tumour motion as a result of respiration. However, as 4DCT enables the GITV to be 
individually visualised and delineated it is not necessary to include this potential error 
in our margin and hence, this stage is not required. We therefore concentrated on the 
second  stage  of  defining  treatment  margins  which  is  to  calculate  an  uncertainty  of 
position  as  a  result  of  set-up  errors  only.  As  there  can  be  movement  in  three 
dimensions,  the  calculation  has  to  be  performed  separately  for  lateral  movement, 
superior/inferior movement, and anterior/posterior motion. 
 
The McKenzie et al. equation to calculate CTV to PTV margin: 
 
2.5 Σ + a + b + β(σ – σp) 
 
 
Symbol 
 
Explanation 
Σ  Standard deviation of the systematic error. 
a  The photon beam algorithm error. 
b  Motion of the target caused by breathing. 
β 
This  depends  upon  the  detailed  beam  configuration  and  is  given  in  the 
publication. 
σ  Standard deviation of the random error. 
σp  The unblurred photon beam penumbra width. - 51 - 
How each parameter was calculated will be discussed in turn. 
 
1) The Standard Deviation of the Systematic Error (Σ) 
 
Σ represents the systematic errors that are incorporated into the margin in a Gaussian 
fashion. A number of potential systematic errors make up Σ and the value is calculated 
by adding these together in a quadratic fashion. Of these errors, the most significant 
one is the standard deviation of the systematic set-up error. The majority of the other 
errors mentioned such as a phantom transfer error, treatment planning system error 
and LinAC geometry error, are so insignificant that in the face of larger errors being 
added in a quadratic nature, they would have had no effect on the final value and were 
therefore not calculated. The only other systematic error that has the potential to be 
large and may have some effect on the final value is the interclinician variation error 
which will be discussed in some detail later.  
 
To  calculate  the  standard  deviation  of  the  systematic  set-up  error,  a  research 
radiographer reviewed pairs of AP and lateral MV orthogonal iso-images of 100 patients 
retrospectively. Each patient had between 2 and 10 iso-images each taken on different 
fractions for off-line verification. There were 412 images analysed in total. Reference 
landmarks were delineated on the DRR created from the planning CT and then on the 
iso-images.  These  reference  landmarks  were  highlighted  on  the  iso-images  and 
compared to the same landmarks on the DRR produced at planning. The iso-image was 
shifted to match the DRR image as closely as possible. It is important to use reference 
landmarks that are immobile, or do not exhibit any interfraction patient motion, such 
as the paraspinal line, clavicle, trachea, thoracic wall and apex of lung [109,110]. The 
deviation  from  the  iso-image  position  to  the  DRR  position  in  all  three  directions, 
superior/inferior, laterally and anterior/posteriorly was noted. The above analysis was 
performed by the research radiographer, the accumulation of this data and all further 
analysis was performed by myself. All the deviation data was recorded in Microsoft 
Office XL Professional 2007, one page for each direction. To calculate the standard 
deviation of the systematic set up error, the following equation was used: - 52 - 
       
 
Σ set-up =  √ [       P         ∑ np (mp – m overall)
2 ] 
         N (P – 1) 
 
 
 
Symbol 
 
Explanation 
Σ set-up 
 
Standard  deviation  of  the  systematic  treatment  set-up  error  for  all 
patients P in a given direction. 
P 
 
Total number of patients for which images were acquired. 
N 
 
Total number of images in study 
np 
 
Number of images taken for patient p. 
mp 
 
Mean set up deviation for patient P. 
moverall 
 
Overall mean population error. This is the mean systematic set-up error. 
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•  The  anterior  /  posterior  standard  deviation  of  systematic  set-up  error  was 
calculated as:    3.0mm 
 
•  The  superior  /  inferior  standard  deviation  of  systematic  set-up  error  was 
calculated as:    3.0mm 
 
•  The lateral standard deviation of systematic set-up error was calculated as: 
      2.9mm 
 
The inter-clinician variation, which is the difference between GTVs drawn by clinicians, 
has been calculated in a number of papers and the figures vary widely [39,40]. There 
was an attempt to ask clinicians at our own centre to delineate the same patients so to 
enable  site-specific  inter-clinician  variation  to  be  calculated,  but  due  to  time 
constraints  on  our  clinicians  and  the  volume  of  additional  delineation  required  to 
achieve any sort of meaningful figure, this was not possible. It became apparent after a 
few delineations that in lung cancer, the large inter-clinician errors do not occur as a 
result of discrepancies at the edges around the same agreed high density area or lymph 
node, but in deciding whether or not to include a lymph node in the volume or a blood 
vessel in the volume, or an area of opacified lung in the volume. This variation cannot 
easily quantified and added to a margin, as clinicians can identify gross tumour that lies 
centimetres  away  from  the  primary  tumour  in  any  direction  and  incorporating  this 
would likely involve large margins in some directions that bear no relevance to the 
majority of patients. In order to assess whether this made a significant difference to 
the margin we calculated a margin with and without incorporating the error to enable 
us to decide whether it was feasible to incorporate this into the margin recipe. 
To identify a figure for interclinician variation, as it proved impossible to calculate one 
at our centre, we conducted a literature search for an appropriate value. A literature 
search  for  “interclinician  variation”  and  “delineation  variation”  was  undertaken  on 
“PubMed”  and  “ScienceDirect”  for  any  papers  regarding  interclinician  discrepancies 
within the last ten years. Steenbakkers et al. calculated the standard deviation of the 
interclinician discrepancies [24]. This paper was chosen as it had the largest number of - 54 - 
patients and radiation oncologists and it also had a wide range of tumour positions and 
stages. Eleven radiation oncologists were asked to delineate 22 patients. The radiation 
oncologists  were  given  all  the  clinical  information,  all  available  pathology  and  the 
diagnostic scans and asked to delineate the GTV.  The observer variation was computed 
in three dimensions by measuring the distance between the median GTV surface and 
each  individual  GTV.  The  inter-clinician  discrepancy  error,  as  described  by 
Steenbakkers et al. was 4.2mm. This was with the use of PET/CT in planning as most 
patients  are  planned  with  the  assistance  of  PET/CT  scans  at  The  Beatson,  West  of 
Scotland Cancer Centre.  
The margins in all three directions were initially calculated without the inter-clinician 
error for the reasons given above. In this equation, the sole error to be incorporated 
into Σ was the standard deviation of the systematic set-up error. However in addition, 
the  figure  of  4.2mm  was then incorporated  in  a  further  calculation  to  see  whether 
incorporating this error would make a large difference to the final set up error. 
 
 
2) Treatment planning system (TPS) beam algorithm error (a) 
 
This  is  an  error  incorporated  to  allow  for  any  error  in  the  planning  algorithm 
calculation. This would result in a systematic under dosing of the target by the linear 
accelerator beams therefore the margin for this error is added linearly. The 90% dose 
level  is  used  to  determine  the  correction.  The  TPS  beam  algorithm  error  when 
calculated  on  different  systems  falls  between  -2  to  2mm.  2mm  was  used  in  the 
equation as it is the maximum error that could occur and using 2mm would mean all 
potential error would be included in the margin. 
 
 
 
 
3) Breathing positional error (b) - 55 - 
 
This is the amplitude of motion of the CTV caused by respiratory induced motion. As 
discussed above, we plan to address this error by using 4DCT where the GITV already 
encompasses  an  individualised  margin  for  respiration  induced  tumour  motion  and 
hysteresis. We therefore used 0mm in the equation as this is already incorporated in 
the volume.  
 
 
4) Planning Parameter (β) 
 
The  value  of  β  depends  on  the  different  beam  combinations.  A  table  providing  the 
different values for the planning parameter error is present in the document. The value 
chosen depends on the number of beams in use and gives different values for the error 
in transverse and superior / inferior directions.  
•  For a 3 field plan, as is routinely used for radical lung treatments, the value for 
(β) in the superior / inferior direction is 1.64. 
•  For  a  3  field  plan,  the  value  for  (β)  in  a  transverse  plane  with  beams  not 
parallel and opposed is 1.04. 
 
 
5) Treatment execution errors (σ) 
 
The main two parameters that need to be combined in quadrature to give σ are the 
standard deviation of random set-up error and the penumbra width (σp) 
 
To calculate the standard deviation of random set-up error, the same iso-images and 
deviations noted in the calculation of the systematic set-up error were used with the 
following equation to calculate the standard deviation of the random set-up error.  
 
The McKenzie et al. equation for the standard deviation of the random set-up error is: - 56 - 
 
σ set-up =  √ [      1        ∑  σ 2 inter ( np - 1) ] 
   N – P 
 
Symbol 
 
Explanation 
σ set-up 
Standard  deviation  of  the  random  treatment  set-up  error  for  all 
patients P in a given direction. 
P  Total number of patients for which images were acquired. 
N  Total number of images in study 
np  Number of images taken for patient p. 
σ2inter 
Standard  deviation  of  the  inter-fractional  random  treatment  set-up 
error for patient p in a given direction. 
 
•  The  anterior  /  posterior  standard  deviation  of  the  random  set-up  error  was 
calculated as:    0.8mm 
 
•  The  superior  /  inferior  standard  deviation  of  the  random  set-up  error  was 
calculated as:    3.6mm 
 
•  The lateral standard deviation of the random set-up error was calculated as: 
    2.7mm 
 
 
 
 
 
 
6) Photon Penumbra Width (σp) 
 - 57 - 
The penumbra is the area on the edge of the beam that can receive radiation from 
some parts of the source but not from the whole source. This depends on the diameter 
of the source, the source-skin distance and the collimated length. This was calculated 
by the on site Dosimetry Physicists using appropriate parameters for lung cancer plans. 
The penumbra width for a 10cm x 10cm field at 5cm depth was calculated as 8.5mm. 
  
 
•  Van Herk Publication 
 
In order to validate the margin given by the McKenzie equation, a further margin was 
calculated using the van Herk equation: 
 
2.5 ∑ + 0.7 σ 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Results 
 
•  McKenzie Equation - 58 - 
 
The results of the calculations using the McKenzie equation to calculate the CITV to 
PTV margin without adding the interclinician variation are:  
  
In the anterior/posterior position: 
 
Margin =   2.5 Σ + a + b + β(σ – σp)  
Margin =   (2.5 x 3.0) + 2 + 0 + 1.04 [√(8.52 + 0.82) – 8.5] 
Margin =   9.5mm 
 
 
In the superior/inferior position: 
 
Margin =   2.5 Σ + a + b + β(σ – σp) 
Margin =   (2.5 x 3.0) + 2 + 0 + 1.64 [√(8.52 + 3.62) – 8.5] 
Margin =   10.7mm 
 
 
In the each lateral direction: 
 
Margin =   2.5 Σ + a + b + β(σ – σp) 
Margin =   (2.5 x 2.9) + 2 + 0 + 1.04 [√(8.52 + 2.72) – 8.5] 
Margin =   9.7mm 
 
 
The same McKenzie equation was performed but this time incorporating 4.2mm as the 
value  for  inter-clinician  variability  as  discussed  above.  The  results  of  the  further 
calculation are: 
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In the superior/inferior position: 
 
Margin =   2.5 Σ + a + b + β(σ – σp) 
Margin =   (2.5 x √3.02+4.22) + 2 + 0 + 1.64 [√(8.52 + 3.62) – 8.5] 
Margin =   16.1mm 
 
•  Van Herk Equation 
 
The results of the calculations using the van Herk equation to calculate the CITV to PTV 
margin are: 
 
In the anterior/posterior position: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 8.1mm 
 
In the superior/inferior position: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 10.0mm 
 
In the each lateral direction: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 9.1mm 
2.4 Discussion 
 
These two equations are different and either can be used taking into account certain 
caveats. The Van Herk equation was calculated so that 90% of patients receive at least - 60 - 
95% to the CTV. In the McKenzie equation, the objective was to have a large enough 
margin between the edge of the incident radiation beam and the CITV that over the 
course  of  the  fractionated  schedule  the  accumulated  dose  is  >95%.  Both  equations 
imagined the penumbra to be blurred. This blurring occurs due to the motion between 
the target and the beam, both due to day-to-day differences over the treatment course 
and target motion during a fraction. As a result both equations are only applicable to 
fractionated treatments and cannot be used in hypofractionated treatments such as 
SBRT. The main problem with the Van Herk equation is that it is calculated presuming 
the tumour is a perfect sphere, and treatment is entirely conformal. This results in a 
“fringe dose” where there is a background dose because of the penumbras of multiple 
other beams. McKenzie et al. address this by removing this fringe dose so that it can be 
applied with less beams and less conformal treatment hence calculation for an onsite 
penumbra. Despite these slight differences, it is reassuring to note the similar results 
obtained in both calculations.  
 
The addition of the inter-clinician error resulted in a significant increase the margins. 
However, whether or not to use this larger margin has to be considered. One has to ask 
whether  the  incorporation  of  inter-clinician  value  will  increase  the  likelihood  of 
covering 90% of patients with a minimum dose of 95% as the two margins are designed 
to do. The inter-clinician variation in lung cancer tends to be whether or not to include 
a structure, rather than a delineation line falling a few millimetres symmetrically round 
an agreed structure. To incorporate this error would increase the margin by around 
6mm however as different clinicians identify different areas of gross tumour that are 
usually  more  than  6mm  from  the  primary  GTV  this  addition  is  unlikely  to  improve 
tumour coverage. A true interclinician variation would be the estimate of the error 
drawing lines around agreed structures, these would be very small and added together 
in quadrature, would likely not influence the margin. We therefore plan to use the 
margin calculated without the incorporation of an inter-clinician variation error.  
This  work  highlighted  the  need  to  improve  interclinician  variation  within  the 
department.  Since  this  work  was  carried  out  there  has  been  a  planning  meeting 
introduced  where  volumes  are  assessed  by  all  clinicians.  There  is  a  radiologist  and - 61 - 
nuclear medicine physician present to assist with the interpretation of images. There 
are also proposals being put together to import the PET images into the delineation 
system to reduce this further.  
 
As most centres have improved their set up with online imaging, or use shrinking action 
protocol or the no-action level protocol, it is difficult to find papers using a similar off-
line  verification  technique  from  recent  years.  However  in  2001,  Hurkmans  et  al. 
published a review of set up errors in the thoracic region. These were with different 
immobilisation  techniques  but  prior  to  the  advent  of  online  imaging.  The  standard 
deviation  of  the  systematic  error  ranged  from  1.8mm  to  5.1mm  and  the  SD  of  the 
random error ranged between 2.2mm and 5.4mm. Our set up errors are on the better 
end of these figures, probably as a result of improved immobilisation and the vague, 
subjective off-line review technique that we use [111]. 
 
As most of the values calculated were 10mm +/- 2mm, and the fact it is easier in a 
large institution to have one value for all directions, consequently a margin of 10mm is 
recommended for set-up margin for further investigation.  
 
 
 
 
 
 
 
 
 
3. THE USE OF THE MAXIMUM INTENSITY PROJECTION (MIP) FOR TARGET OUTLINING IN 
4DCT RADIOTHERAPY PLANNING. 
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3.1 Introduction 
 
As  discussed  in  the  introduction,  the  intra-fraction  movement  of  lung  tumours  for 
radical radiotherapy is currently encompassed within the margin between the CTV and 
the ITV. With the traditional method of Helical CT scans for conformal planning, the 
intra-fraction movement, due primarily to respiration, cannot be quantified accurately, 
therefore  a  standard  “population-based  margin”  is  applied.  The  margin  applied  is 
crudely  assessed  for  each  individual  patient  in  turn  using  fluoroscopy  at  the 
radiotherapy simulator and altered only if the tumour is obviously moving out with the 
PTV.  
 
The system to create 4DCT’s used in both centres where this work was carried out is 
discussed in detail in section 1.3.2 (page 20). Figure 3-1 illustrates this further. As is 
discussed, there are a few different images created; the phase bins of the different 
respiratory cycles, the MIP, the MinIP and the Ave-IP as seen in Figure 1-4.  - 63 - 
Figure 3-1 An illustration of how the 4DCT scan is captured. The respiratory cycle is the 
motion of an external surrogate on the xiphisternum. During each respiratory cycle, 
20mm  of  chest  is  imaged  10  consecutive  times.  Each  image  captured,  taken  at  a 
different phase of respiration is demonstrated by the image-set names 0%, 10%, 20%.. 
to ..90%. During sorting of the images, all the images corresponding to a specific phase 
of the respiratory cycle (eg. maximum inspiration or 0%) are put on top of one another, 
to create an image-set of maximum inspiration that is in fact the combination of a 
large number of images taken over a large number of respiratory cycles. Ten different 
image-sets  are  created  in  this  way  representing  different  phases  of  the  respiratory 
cycle. 
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There  have  been  various  methods  of  creating  a  GITV  or  CITV  from  a  4DCT  dataset 
reported. Whether it is a GITV or CITV depends on whether the clinician is delineating 
the gross tumour or the gross tumour with a margin for microscopic disease on the 
4DCT. The first, most robust, but time consuming method, is to create a GTV or CTV on 
each of the 10 image-sets representing 10 phases of the respiratory cycle from the 
4DCT dataset and combine these to create the GITV or CITV.  
 
As radiotherapy centres implement 4DCT into planning, a limiting factor to clinical use 
is the time taken to delineate 10 scans for each patient. An alternative delineating 
method might be to use the MIP image set to create the GITV or CITV. One of the first 
questions that will be asked by centres implementing 4DCT is whether the GITV created 
using the MIP image, accurately represents the GITV or CITV. The advantage of this 
method is that once the MIP image set is produced, it comprises just one CT scan that 
should  take  no  longer  to  volume  than  the  current  3D  helical  scans.  In  a  stretched 
radiotherapy centre such as the Beatson, this would obviously the ideal, we therefore 
elected to investigate the safety of this method further. 
 
There is conflicting evidence in the literature regarding the use of MIPs for delineation. 
For Stage I lung tumours, Underberg et al. compared GITV_MIP (a GITV created using 
the MIP image) with GITV_10phase (a GITV created by making a composite of GTVs 
delineated  on  each  of  the  10  bins  in  turn)  which  is  the  gold  standard  method  of 
delineation, in 12 patients [112]. They concluded that contouring of MIP scans was a 
reliable and fast clinical tool for generating GITVs. In the discussion, concerns were 
raised regarding the use of MIP in more advanced tumours. For node positive tumours, 
Ezhil et al. compared GITV_MIP to GITV_10phase in 27 patients with Stage I – III NSCLC 
[113]. They concluded that for all stages of disease, the GITV_MIP was significantly 
smaller in volume than the GITV_10phase.  
 
As  MIP  is  the  most  efficient  method  reported,  we  felt  there  was  a  lack  of  a 
comprehensive  study  to  ascertain  whether  it  is  safe  to  delineate  using  the  MIP, 
especially in node positive patients. Although the Ezhil et al. suggested the GITV_MIP is - 65 - 
smaller  than  the  true  GITV  seen  with  GITV_10phase,  this  required  additional 
confirmation. Consequently, it was elected to investigate whether the MIP image can 
be  used  in  node-positive  patients  who  constitute  the  majority  of  patients  receiving 
radical radiotherapy.   
 
 
3.2 Methods 
 
CT image acquisition 
All patients were routinely immobilised using a Sinmed Posirest Thoracic Board (Sinmed 
BV, The Netherlands) and a knee support prior to scanning on a GE Lightspeed RT 16 
Multi-slice  CT  scanner  (GE  Healthcare,  UK).  Fifty  millilitres  of  Omnipaque  300 
intravenous contrast was administered by Stellant Contrast Injector. A helical scan was 
acquired  followed  immediately  by  a  4DCT  taking  a  total  <3minutes.  Patients  were 
asked to breathe freely throughout and scans covered the whole chest cavity.  
 
4DCT  scanning  was  performed  using  the  Varian  Real-Time  Positioning  Management 
System as described in detail in section 1.3.2 (page 20). Scanning parameters were set 
at 120 kV, 20mA with a slice thickness of 2.5mm. A block containing infrared-reflecting 
markers was placed on the patients’ xiphisternum to monitor respiration. The motion of 
the block was captured by a camera fixed to the end of the treatment couch and a 
respiratory signal was displayed in the control room. For each patient the respiratory 
cycle was assessed. The cine-duration, which is the period of time for which the couch 
is static and images are acquired, was set as the mean respiratory cycle length for that 
patient plus 0.5 seconds. The X-ray tube rotation was set to 1/10th of the respiratory 
cycle length. In each static couch position, 8 contiguous slices of 2.5mm were acquired. 
The couch position was indexed by 20mm and the process repeated. Mean respiratory 
cycle lengths ranged from 2.9s to 7.9s. The helical scan acquisition time was about 18 
seconds and the 4DCT acquisition time was about 90 seconds. 
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The 4DCT dataset was transferred to an Advantage 4D workstation (GE Healthcare, UK) 
where  a  software  package  was  used  to  create  10  different  scan  sets  relating  to  10 
sequential phases of the respiratory cycle, using the amplitude of the respiratory trace. 
These are labelled 0%, 10%, …. ,  90%. The 4D software was also used to create a scan 
MIP from the raw data as described in section 1.3.2. 
 
Patient Selection 
This was a retrospective analysis for patients who had undergone both Helical and 4DCT 
for their radical radiotherapy planning. Fourteen consecutive patients, presenting to 
one consultant with radically treatable NSCLC, over a 4 month period, were studied.  
 
Generating Target Volumes 
The target outlining in all 14 patients was completed by the author. Helical scans were 
transferred directly from the scanner to the Varian Eclipse Treatment Planning System, 
software  version  6.5  (Varian  Medical  Systems,  Palo  Alto,  CA).  The  4DCT  was  sent 
initially to ADW and once the creation of the respiratory bins had occurred, they were 
also  transferred  to  the  Varian  Eclipse  Treatment  Planning  System.  The  scans  were 
viewed and outlined in the Beatson’s standard mediastinal and lung window settings (-
130HU  to  200HU  and  -1000HU  to  -200HU,  respectively).  The  CTV’s  of  the  primary 
tumour  included  all  gross  disease,  with  a  margin  added  manually  of  approximately 
3mm. Lymph nodes were included if they measured >1cm in diameter and were also 
given a margin of around 2-3mm to account for microscopic disease.  
On the MIP image set, the gross tumour was delineated with a margin of ~3mm for 
microscopic disease. This created a CITV and was labelled CITV_MIP. 
To create the composite volume from all 10 phases (CITV_10phase), each of the 10 
phase image sets was contoured individually to create 10 CTVs. The images were all 
registered  to  a  reference  image,  and  CTVs  from  each  phase  were  copied  onto  the 
reference image. Algebraic operators were used to create the CITV_10phase.  
The MIP image was also registered with the reference image and the CITV_MIP was 
copied across so that it could be compared directly with the CITV_10phase. 
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Analysis of Target Volumes 
The volumes of the two CITVs were compared by calculating the ratio between them. 
The  regions  on  the  scan  where  the  volumes  most  differed  were  noted.  Algebraic 
operators were used on the Varian Eclipse system to determine the volume of tissue 
enclosed by the CITV_10phase but not by CITV_MIP and, likewise, the volume of tissue 
enclosed by the CITV_MIP but not the CITV_10phase. The centre of mass co-ordinates 
(COM co-ordinates) of both volumes were recorded and compared. 
 
Statistical Analysis 
Wilcoxon signed-rank test, calculated on SPSS 15.0 for Windows, was used to compare 
volumes. A p≤0.05 was considered statistically significant. 
 
 
 
3.3 Results 
 
Tumour stages varied from Stage IB to Stage IIIB (Table 3-1). 
 
Comparison of CITV_10phase to CITV_MIP 
These results are presented in Table 3-2. In all patients the CITV_10phase was equal to 
or larger than the CITV_MIP. The mean ratio (+ S.D.) of CITV_10phase /CITV_MIP was 
1.23 ± 0.17. The 95% confidence interval was between 1.13 and 1.32. The Wilcoxon 
Signed-Rank test showed there was a statistically significant difference between the 
two volumes (p= 0.001).  
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Table 3-1. Tumour Characteristics 
 
 
 
Patient 
 
TNM stage 
 
Stage 
 
Position 
       
Patient A  T2 N0  Stage IB  LLL 
Patient B  T2 N0  Stage IB  LUL  
Patient C  T2 N2  Stage IIIA  RML. Partial collapse of RML 
Patient D  T4 N0  Stage IIIB  Rt pancoast tumour 
Patient E  T4 N2  Stage IIIB  Rt pancoast tumour 
Patient F  T2 N1  Stage IIB  RUL. Collapsed RUL. 
Patient G  T2 N2  Stage IIIA  RML. Adjacent to hilum 
Patient H  T4 N2  Stage IIIB  LLL. Infiltrating pulmonary artery 
Patient I  T1 N2  Stage IIIA  LUL. Adjacent to hilum 
Patient J  T2 N2  Stage IIIA  RLL. Adherent to diaphram 
Patient K  T2 N1  Stage IIB  RML. Adjacent to hilum 
Patient L  T0 N2  Stage IIIA  Mediastinal recurrence following lobectomy 
Patient M  T2 N1  Stage IIB  RUL  
Patient N  T2 N1  Stage IIB  RML. Adjacent to hilum 
 
LUL – left upper lobe. LLL – left lower lobe. RUL – right upper lobe. RML – right mid 
lobe. RLL – right lower lobe. 
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Table 3-2. Comparison of CITV_10phase to CITV_MIP 
 
 
 
CITV_10phase 
(cm3) 
CITV_MIP 
(cm3) 
 
Difference in 
Volumes 
(cm3) 
CITV_10phase/ 
CITV_MIP 
 
Patient A 
 
37.0 
 
36.8 
 
0.2 
 
1.01 
Patient B  26.0  24.9  1.1  1.04 
Patient C  140.1  116.2  23.9  1.21 
Patient D  96.2  80.4  15.8  1.20 
Patient E  67.2  52.2  15.0  1.29 
Patient F  120.1  94.3  25.8  1.27 
Patient G  111.4  91.5  19.9  1.22 
Patient H  99.4  87.5  11.9  1.14 
Patient I  112.5  87.3  25.2  1.29 
Patient J  215.8  138.9  76.9  1.55 
Patient K  71.2  63.2  8.0  1.13 
Patient L  40.4  26.2  14.2  1.54 
Patient M  51.7  39.0  12.7  1.33 
Patient N  37.2  37.0  0.2  1.01 
         
Mean +/- S.D        1.23 +/-0.17 
Median        1.22 
P-value        0.001 
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The median percentage of CITV_10phase, or potentially tumour tissue, which was not 
covered by the CITV_MIP, was 19.0% (range 5.5% – 35.4%) (Table 3-3). There was good 
agreement  in  delineation  in  areas  where  the  higher  density  tumour  adjoined  lower 
density  lung  tissue.  However,  significant  differences  in  delineation  occurred  where 
tumour  adjoined  the  mediastinum  or  diaphragm  i.e.  where  the  tissue  has  a  similar 
density  to  tumour.  This  is  demonstrated  in  Figure  3-2.  The  median  percentage  of 
CITV_MIP that was not covered by CITV_10phase was 2.3% (range 0.4% - 9.8%) (Table 3-
4). These areas were randomly distributed around the circumference of the volume and 
relate to very small displacements of the contour lines. 
 
In  the  two  patients  with  Stage  I  disease  (Patients  A  and  B),  the  CITV_MIP  and 
CITV_10phase volumes were very similar with the ratios of 1.01 and 1.04 (Table 3-2). 
Only  6.8%  and  5.5%  of  CITV_10phase  was  not  enclosed  by  MIP  (Table  3-3).  These 
tumours were entirely surrounded by low density lung tissue and contour lines were 
again displaced by very small distances.  
 
Comparison of COM co-ordinates 
The COM co-ordinates and calculated displacement of centres are shown in Table 3-5. 
In the superior/inferior axis, medio-lateral axis and anterior/posterior axis the mean 
distance between co-ordinates was 0.15cm, 0.13cm and 0.07cm respectively. The mean 
(+ S.D.) displacement of the centres was calculated as 0.34cm (±0.31). There were 5 
patients with a displacement of COM of ≥0.4cm. This level of displacement would cause 
a significant systematic error affecting ITV to PTV margin. - 71 - 
Table 3-3. The percentage volume covered by CITV_10phase that remained uncovered 
by CITV_MIP. 
 
 
 
 
 
 
 
Volume of CITV_10phase 
not encompassed by 
ITV_MIP (cm3) 
Volume of CITV_10phase 
(cm3) 
% of CITV_10phase not 
encompassed by ITV_MIP 
 
Patient A 
 
2.5 
 
37.0 
 
6.8 
Patient B  1.4  26.0  5.5 
Patient C  30.9  140.1  22.1 
Patient D  11.6  96.2  12.1 
Patient E  15.0  67.2  22.3 
Patient F  23.1  120.1  19.2 
Patient G  17.2  111.4  15.4 
Patient H  18.0  99.4  18.1 
Patient I  25.1  112.5  22.3 
Patient J  76.4  215.8  35.4 
Patient K  13.4  71.2  18.8 
Patient L  13.0  40.4  32.2 
Patient M  11.4  51.7  22.1 
Patient N  2.5  37.2  6.6 
       
Mean +/- S.D      18.5 +/- 8.5 
Median      19.0 - 72 - 
Table  3-4.  The  percentage  volume  covered  by  CITV_MIP  that  is  uncovered  by 
CITV_10phase. 
 
 
 
 
 
 
 
 
Volume of CITV_MIP not 
encompassed by 
CITV_10phase (cm3) 
Volume of CITV_MIP (cm3) 
 
% of CITV_MIP not 
encompassed by 
CITV_10phase 
 
Patient A 
 
1.3 
 
36.8 
 
3.6 
Patient B  0.2  24.9  0.9 
Patient C  2.0  116.2  1.7 
Patient D  0.3  80.4  0.4 
Patient E  2.5  52.2  4.9 
Patient F  0.5  94.3  0.6 
Patient G  0.5  91.5  0.5 
Patient H  7.5  87.5  8.6 
Patient I  1.9  87.3  2.2 
Patient J  3.5  138.9  2.6 
Patient K  6.2  63.2  9.8 
Patient L  0.6  26.2  2.4 
Patient M  0.7  39.0  1.7 
Patient N  2.7  37.0  7.4 
       
Mean +/- S.D      3.4 +/- 3.0 
Median      2.3 - 73 - 
Table 3-5. The COM Co-ordinates in the two different volumes (cm).  
x= left/right axis, y= anterior/posterior axis, z= superior/inferior axis. 
 
 
  CITV_10phase  CITV_MIP 
 
Distance between 
centres 
  x,  y,  z  x,  y,  z  (cm) 
 
Patient A 
 
3.5,1.5,1.3 
 
3.9, 1.8, 1.3 
 
0.45 
Patient B  6.9, 8.1, -7.8  6.9, 8.1, -7.9  0.06 
Patient C  -6.0,-4.2, 1.0  -6.2, -4.2, 1.0  0.23 
Patient D  -6.7, 5.0, 11.7  -6.7, 5.0, 11.8  0.10 
Patient E  -5.0, 1.5, 7.6  -5.5, 1.7, 8.5  1.05 
Patient F  -3.7, -0.2, 6.2  -3.7, 0.0, 6.3  0.11 
Patient G  -2.7, -0.1, 1.0  -2.7, 0.0, 1.1  0.13 
Patient H  8.6, 5.5, -3.3  8.6, 5.5, -3.3  0.04 
Patient I  5.2, 0.5, -0.1  5.5, 0.4, 0.2  0.45 
Patient J  -7.0, -0.3, -2.2  -6.3, -0.1, -1.6  0.96 
Patient K  -8.3, 3.0, 0.8  -8.7, 3.3, 1.0  0.53 
Patient L  -0.9, -1.4, 4.8  -0.9, -1.5, 4.6  0.21 
Patient M  -4.6, 1.5, 7.0  -4.8, 1.7, 7.0  0.25 
Patient N  -5.8, -0.4, -3.6  -5.7, -0.4, -3.5  0.16 
       
Mean ± S.D.      0.34 ± 0.31 
Median      0.22 
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Figure  3-3.  A  coronal  view  of  a  planning  4DCT  with  CITV’s  created  using  different 
methods. The CITV_10phase is in cyan and the CITV_MIP in red. This demonstrates the 
high density areas missed by the CITV_MIP. 
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3.4 Discussion 
 
This study suggests that CITV_MIP cannot be used for accurate delineation of Stage II-III 
tumours  as  there  are  significant  volumes  of  tumour  tissue,  identified  by  the 
CITV_10phase, that are not encompassed by the CITV_MIP. In contrast, CITV_MIP could 
be used for Stage I tumours, but this is based on data from only two patients.  
 
Although we have only limited data, and hence statistical findings may not be robust, 
18.5%  of  uncovered  tumour  is  sufficient  to  raise  concerns  regarding  this  method. 
Allowing for the fact there were only two Stage I patients it is reassuring to find the 
results in these patients are in keeping with the findings of Underberg et al., that an 
ITV  created  using  a  MIP  image  is  reliable.  The  concerns  regarding  locally  advanced 
tumours mentioned in that discussion are corroborated by this study. Figure 3-3, used 
to illustrate the problems with MIP in locally advanced tumours, resembles the image 
used in the discussion of the Underberg paper. It is reassuring to note that even given 
the different observers and patient group, the conclusion remains the same. 
 
For those with experience in the use of 4DCT datasets, this is not a surprising finding. 
For  most  patients  with  Stage  1  NSCLC,  a  discrete  tumour  mass  moves  within  much 
lower  density  lung  tissue,  allowing  large  differences  in  density  providing  obvious 
contour lines.  In patients with Stage II-III, the tumour mass will be adjacent, at least 
on some boundaries, to tissue of equal density, such as mediastinum, chest wall or 
diaphragm. A boundary between tumour and normal tissue may be clearly visible on 
any individual phase scan. On the MIP image, boundaries become blurred. There is a 
natural tendency towards presuming that tissue is ‘normal’ unless there is evidence 
otherwise and so the extent of disease tends to be underestimated on the MIP. It is 
possible  that  individual  nodes  may  not  be  identified. T his  is  an  important  point  to 
highlight  to those beginning to use 4DCT, and a further discussion regarding alternative 
techniques will take place in more detail below.  
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The information from a diagnostic PET/CT was not available for this group of patients 
as it was not in routine use at the time of the planning scans. Although the use of 
PET/CT has a significant effect on inter-clinician variability, it should not impact on 
intra-clinician variability.  As there is no consensus on what level of SUV, or percentage 
of SUV, constitutes the tumour edge [39,114] PET/CT should be used for localisation 
purposes  rather  than  delineation.  Although  it  may  have  highlighted  different  nodal 
groups, hence increasing the CITVs, the intra-observer variation would be the same, 
hence generating the same outcome. 
 
The  intra-observer  variation  goes  some  way  to  explain  why  in  all  cases  the 
CITV_10phase is bigger than CITV_MIP. Intra-observer variations in PTV are reported to 
vary from 3.9cm
3 to 95.8cm
3 [115]. The algebraic method of adding volumes means that 
small drawing variations in different bins always forms a larger composite volume than 
if one volume alone was delineated as in CITV_MIP. As a result, small differences in 
CITVs such as 0.2cm
3 or 1.1 cm
3, as in the Stage I tumours, are likely due only to intra-
observer variation, rather than a difficulty in delineating the tumour. 
 
The creation of the CITV in the above manner with gross tumour and an additional 
margin of approximately 3mm, was adopted as a standard throughout all patients. For a 
more accurate addition of 5mm for microscopic disease, a GITV would be created with 
any of the below methods, and thereafter a margin of 5mm would be added to create 
the CITV. Although, for some, the method used in this study would not be standard 
delineation margins, what is important in the validity of the study is that the method 
used  is  consistent.  As  it  is  widely  accepted  that  interclinician  discrepancies  remain 
high, there would be disagreement from some whichever method was used. The study 
remains valid as there was a consistent method used throughout all the delineation. 
The window levels were not according to EORTC guidelines however the same values 
were used throughout the study [116]. 
 
The  major  practical  drawback  to  the  use  of  ITV_10phase  is  the  long  operator  time 
required. Delineation of 10 scans and creation of composite volumes takes on average - 77 - 
2.5  hours  per  patient  and  it  is  very  desirable  to  reduce  this  time  requirement.  A 
number of alternative methods have been reported in the literature: 
1)  Ezhil  et.al.  [108]  described  the  creation  of  a  structure  labelled 
ITV_MIP_Modified. The ITV was delineated on the MIP image and this volume was 
superimposed onto each of the 10 phases in turn, where it was modified by only 
enlarging  boundaries  when  appropriate.  The  ITV_MIP_Modified  was  in  close 
agreement with ITV_10phase.  This could offer some time savings but remains a 
work intensive method.  
2) A number of studies created an ITV from a composite of the two scans with the 
tumour in the most superior and inferior position [51,117]. There are a number of 
concerns  with  this  method.  This  does  not  take  into  account  lateral  or 
anterior/posterior  motion  of  the  tumour  nor  hysteresis.  There  is  also  evidence 
describing  the  lack  of  correlation  between  the  primary  tumour  and  lymph  node 
movement [118,119]. When selecting the two scans for delineation it may be that 
the primary tumour and involved lymph nodes are at their craniocaudal extreme 
positions in different scans. Care must also be taken to review the 4DCT cinescan in 
all planes. The method can be used if careful review of the 4D window cinescan 
takes  place,  in  all  planes,  noting  any  areas  of  significant  movement  in  other 
directions. A margin could be added to the ITV to PTV margin for the additional 
movement  and  hysteresis  that  takes  place  as  above.  Unless  used  with  care  and 
experience, this technique could lead to geographical miss of disease. 
3) Wolthaus et.al. [120] reported a method for constructing a single CT scan from 
the 4D dataset which represents the tumour in its time-averaged position over the 
respiratory cycle (mid-ventilation scan). Whilst diaphragm movement could be used 
to quickly identify the mid-ventilation scan for Stage I tumours, for Stage II and III 
disease, delineation of all 10 phases was required, which is the time-consuming 
process we are trying to avoid.   
4)  Bosmans  et  al.  [121]  described  a  method  where  the  4D  cinescan  is  used  to 
identify  the  scan  where  the  tumour  is  in  its  central  position  and  measure  the 
motion of the tumour in all three orthogonal directions. After delineating a CTV on 
the half ventilation scan individual margins are added which are calculated using - 78 - 
the  motion  seen  on  the  4D  cinescan.  The  volumes  created  in  this  method  are 
comparable in the above paper.  
5)  There  are  a  number  of  other  methods  reported,  using  different  imaging 
techniques for individualising margins including; slow CT [122], end-tidal breath-
hold CTs [123], composite of 2 different helical scans in maximal inhale and exhale 
[124] and breath-hold CT [125], however each of these have their drawbacks and as 
software and systems have moved on, the 4DCT dataset is now regarded as the gold 
standard. 
 
Although  there  is  evidence  that  normal  tissue  irradiation  is  reduced  and  target 
localization improves with the use of individualized margins, it has to be noted there is 
a lack of clinical outcome data. As with the introduction of conformal radiotherapy, 
there is a general consensus within clinical circles that this constitutes an improvement 
from current techniques and a randomised control trial of 3D versus 4D planning scans 
may be difficult to recruit to on ethical grounds. Clinicians may feel 3D planning scan 
may constitute sub-optimal treatment. Hence a comparative study with outcome data 
and cost effectiveness data is unlikely to occur. 
 
For Stage II and III disease, with the planning system Eclipse Version 8.4 (Varian Medical 
Systems, Palo Alto, CA) that was in use during this study, using a 4DCT was not possible 
in routine patients due to time limitations involved in delineating ITV_MIP_Modified or 
ITV_10phase.  This  was  primarily  because  the  different  image-sets  were  not 
automatically registered and volumes could not be combined easily between different 
image-sets. However since the study was completed, there has been an upgrade to 
Version  8.6.  This  version  has  undergone  significant  improvements  to  software  and 
permits automatic matching and registration across multiple image sets where they are 
already  DICOM  matched  i.e.  they  have  been  acquired  in  the  same  scan  process.  In 
addition,  it  allows  blending  of  different  image-sets  so  volumes  delineated  on  one 
image-set  can  be  manipulated  while  viewing  a  different  image-set.  Since  the 
implementation of Version 8.6 we have put together a protocol for delineation of Stage - 79 - 
II-III  NSCLC  which  is  very  similar  to  ITV_MIP_Modified  which  we  know  from  the 
literature is comparable to the gold standard of delineating all 10 phases.  
The steps involved in delineation of a node positive tumour are as follows: 
1)  The  4DCT  movie,  created  by  running  all  10  respiratory  phases  together,  is 
reviewed on Eclipse 8.6. 
2) The phases where the tumour is in the most extreme position in all 6 directions 
are identified. These often fall within the same 2 phases, representing expiration 
and inspiration but any number can be selected to ensure the extreme of position is 
captured. 
3) All the delineating is saved onto the Ave-IP, as this is the image-set that will be 
used for calculation, although this image-set is never visualised.  
4) The first image-set that was selected in step 2 is blended with Ave-IP, so that 
although the volume is being saved on Ave-IP, only the image-set selected is being 
seen, and a GITV is delineated.  
4) In turn, all the image-sets selected in step 2 are blended with Ave-IP and the 
GITV is enlarged with each image-set to encompass all gross tumour in all phases of 
the respiratory cycle. 
5) It is vital to remember that the GITV can only ever be enlarged. Although the 
gross tumour may not appear on the image-set being visualised, it has been present 
on a previously reviewed image-set as it has been included in the volume. 
 
In conclusion, in the meantime, in our centre, in Stage 1 disease, if the tumour does 
not sit adjacent to high density structures, we propose the use of target delineation on 
the  MIP  image-set  target.  In  Stage  II-III  disease,  we  will  use  the  method  described 
above.  
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4. FEASIBILITY OF MV-CINE FOR VERIFICATION OF INTRAFRACTION TUMOUR MOTION.   
 
 
4.1 Introduction 
 
In the past, small irregularities in intrafraction tumour motion were not so clinically 
relevant due to the fact offline verification protocols resulted in large margins and 3D 
conformal  therapy  plans  lacked  the  conformality  of  IMRT  plans.  However  recent 
changes  in  radical  radiotherapy  in  lung  cancer  have  resulted  in  the  assessment  and 
verification of intrafraction respiration induced tumour motion becoming increasingly 
important: 
1)  New,  sophisticated  planning  and  delivery  techniques  such  as  IMRT  [126], 
stereotactic  radiation  therapy  (SRT)  [14]  and  Tomotherapy  [127]  can  produce 
increasingly conformal treatment plans.  
2) It is also known that these technologies are labour-intensive and can lead an 
increase in treatment times [128] which in turn increases the risk of intrafraction 
shifts in tumour position [68].  
3) Due to the complexities of these delivery techniques concerns have been raised 
that therapy may be more error-prone [129].  
 
The  issue  of  verification  of  the  intrafraction  respiration  induced  tumour  motion  on 
treatment remains one for which there is no consensus. The relatively short duration of 
acquisition of 4DCT contrasts with the far longer duration of treatment delivery. All 
these  factors  have  led  to  calls  for  the  development  of  methods  of  independent 
verification of treatment delivery, in order to pick up the minority of patients with 
significant errors during treatment delivery [124].   
 
Quality  assurance  in  radiotherapy  would  improve  if  IGRT  allowed  for  repeated 
verification of tumour position during treatment delivery, either directly or via other 
internal surrogates, during the delivery of the radiation. The position of the carina can - 81 - 
be used as an internal surrogate as previous work had shown a good correlation with 
total lung volumes [130] and recent studies have confirmed the correlation between 
the  carina  and  3D  tumour  position  [131].  Real  time  tumour  tracking  using  fiducial 
markers is not commonly performed, as insertion can be technically difficult, there is a 
significant  risk  of  pneumothorax  [81]  and  there  are  high  drop-out  rates  after 
bronchoscopic  placement  [82].  Electronic  portal  imaging  device  (EPID)  images  have 
been  used  previously  for  off-line  set  up  assessment  as  they  enable  the  internal 
structures during treatment delivery to be visualized [132]. These MV images involve no 
extra dose to the patient and require no prolongation of radiation delivery. However, 
the limited image quality with MV imaging was previously considered a drawback. With 
recent advances in this imaging technology, megavoltage planar images have been re-
evaluated  using  phantom  studies.  In  their  current  form,  megavoltage  planar, 
kilovoltage (kV) planar, and cone beam computed tomography imaging systems, on a 
Varian linear accelerator, have been reported to be of sufficient quality as to allow for 
image-guidance  approaches  [133].  The  possibility  of  using  an  MV  cine-image,  which 
refers to a number of consecutive MV image frames run together to create a movie, has 
been used together with and without implanted fiducial markers for quality assurance 
of gated treatment delivery [134,135].   
 
The hypothesis was that if internal structures could be visualized on MV-cine without 
use  of  fiducial  markers,  review  of  these  images  could  potentially  provide  off-line 
information  on  both  intrafractional  and  interfractional  motion,  with  no  increase  in 
treatment  time  or  radiation  dose.  Preliminary  data  from  patients  supported  this 
hypothesis [ 136].  The  aim  of  the  present  study  was  three-fold:  firstly  to  identify 
intrathoracic  structures  which  could  be  visualized  consistently  during  thoracic 
radiotherapy in stage III NSCLC; secondly, to identify factors which impaired the quality 
of MV-cine; and finally, to assess the residual motion of the same structure (internal 
surrogates) relative to motion observed on the planning 4DCT.  
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4.2 Materials and Methods 
 
Radiation Planning and Delivery 
This was a single-centre retrospective analysis of consecutive patients who had recently 
undergone radical conformal external beam radiotherapy for non-small cell lung cancer 
at the VU Medical Centre (VUMC). All such patients routinely underwent a 4DCT scan, 
performed on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) with 
the use of a Varian Real-Time Positioning Management System (RPM; Varian Medical 
Systems, Palo Alto, CA) as described in section 1.3.2. In order to select patients the 
4DCT  was  reviewed  on  the  Advantage  4D  workstation  (GE  Healthcare,  UK)  by  a 
clinician. The maximum 2D movement of the tumour was measured in the coronal view 
of the movie with the straight line measuring device. Motion measurements were taken 
for the apex of the tumour, the inferior border of the tumour, the lateral edge of the 
tumour and the carina. The maximum tumour movement was noted as the largest of 
the  three  tumour  vectors.  Six  consecutive  patients  with  tumour  movement  of  over 
2.5mm were included in the analysis.  
All patients had treatment plans, consisting of 5-10 fields using 6 or 15 MV photons. 
Routine  daily  patient  positioning  was  performed  using  laser  beams  and  On  Board 
Imaging. Radiotherapy was delivered on a Varian 2300 C/D linear accelerator equipped 
with a 120 multileaf collimator, (Varian Medical Systems, Palo Alto, CA) to total doses 
of between 45Gy to 66Gy in fractions of 2-3Gy.  
The  key  aspect  of  treatment  is  that  it  was  delivered  using  ‘Amplitude  Monitored 
Treatment Delivery’ (AMTD), an approach discussed in section 1.3.3, where the RPM 
trace is continuously monitored throughout treatment. Any increase in amplitude over 
the  amplitude  threshold  set  at  the  planning  4DCT  causes  the  radiation  beam  to 
temporarily stop. AMTD delivery minimizes the likelihood of a systematic difference 
between intra-fraction tumour motion, at 4DCT and during treatment delivery.    
MV-cine were collected from all gantry angles unless two fields had the same gantry 
angle, in which case the field with the largest dimensions was selected on the EPID 
system. The EPID system consists of an image detection unit (IDU) featuring detector 
and  accessory  electronics,  an  image  acquisition  unit  containing  drive,  acquisition - 83 - 
electronics and interfacing hardware, and a dedicated workstation for off-line image 
review (Portal Vision 6.5, Varian Medical systems).  The IDU matrix consist 1024 x 768 
pixels (pixel size: 0.39x0.39mm) enabling a 40 x 30 cm2 sensitive area at 145 cm source 
detector distance, i.e. 27.5 x 20.7 cm2 with typical 100 cm isocenter-based radiation 
techniques. During all MV cine acquisition procedures clinical beam parameter settings 
were  used  (6  MV  photon  energy;  dose  rate  setting  600  MU/Min.).  MV  cine  imaging 
supports fast image capture of 7-8 image frames per second. Figure 4-1 demonstrates 
an MV cine-image with the tumour highlighted. 
 
Retrospective assessment of MV images 
From  each  of  the  first  6  patients  selected  for  review,  MV-cine  of  four  consecutive 
fractions were analyzed. To create the MV-cine, initially they were exported, in DICOM 
format from the patient data base system (ARIA Version 8.5, Varian Medical Systems, 
Palo Alto, CA) to the station’s hard-drive. Software developed in-house for the ImageJ 
program was used to resolve the time order for DICOM-based images in exported stacks. 
ImageJ  is  a  Java-based  image  processing  package  (http://rsb.info.nih.gov/ij/)    that 
was run under the Windows XP operating system on a Pentium 4 processor with 2 GB on 
board access memory.  
 
•  AIM 1: Identification of intrathoracic structures in treatment fields 
Two  independent  observers,  the  author  and  one  research  physicist,  reviewed  one 
fraction of radiation belonging to each patient. They were asked if they could identify 
the  carina,  the  hilum  and  the  tumour  mass  respectively  in  each  field.  Only  if  both 
parties where confident the structure could be identified was the structure noted as 
identifiable.  The  Beams  Eye  View  (BEV)  of  the  treatment  plan  with  the  different 
structures highlighted was available for assistance in identifying structures.   
 
•  AIM 2: Factors which impaired the quality of MV cines images 
To identify characteristics of MV-cine that limited their use, when structures could not 
be identified, the observers were asked to document the reasons for this. To assess the 
minimum number of MU’s necessary to encompass a whole breathing cycle, MV-cine - 84 - 
were also assessed to see whether a complete respiration cycle had occurred during the 
movie and compared to the MU’s used.  Without an entire breathing cycle, internal 
structure movement would be underestimated, and therefore there is limited value in 
analyzing these images. 
 
•  AIM 3: Comparison of motion of a structure on MV cine-image versus motion on 
4DCT. 
Finally, the two-dimensional (2D) motion path for several thoracic structures on MV-
cine images, were measured offline using experimental research software (RPM-Fluoro 
tool kit version 0.7.5, Varian Medical Systems, Palo Alto, CA). The 2D motion path is 
calculated  by  highlighting  the  internal  structure  on  the  first  frame  of  the  MV  cine-
image with a reference box and using the markerless tracking tool. The reported 2D 
distance  the  internal  structure  moved  is  the  beam’s  eye  view  2D  displacement  of 
markers from their expected home position. See Figure 4-2 for a flow chart on creation 
of MV cine-image and analysis of movement. 
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Figure 4-1. Megavoltage image with tumour mass highlighted. 
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The RPM-Fluoro Tool 
A research software tool, the RPM-Fluoro Tool (Varian Medical Systems, Palo Alto, Ca) 
was used to quantitatively assess the motion of all three internal structures. The RPM-
Fluoro Tool was installed on same independent station hard-drive as the MV-cine. To 
review a MV cine-image and to calculate motion, the relevant MV cine-image file was 
selected  from  hard-drive.  This  toolkit  is  able  to  track  obvious  soft-tissue  targets 
without the need for implanted marker seeds. The markerless registration and tracking 
method  is  based  on  spatial  template  matching.  Because  the  target  appearance  in 
radiographic images is often quite different at different breathing phases, reference 
images  should  generally  capture  target  motion  over  the  whole  breathing  cycle.  For 
each  incoming  frame  the  registration  algorithm  goes  through  a  subset  of  reference 
images to find a best spatial match.  Figure 4-3 demonstrates screen-shots of the RPM-
Fluoro Tool with each of the internal structures highlighted with a reference box.  
Two short assessments were made of the RPM Fluoro-Tool. Firstly there was a phantom 
assessment to validate the measurements it produced, then an assessment for an 
operator difference.  
 
1.  Phantom assessment  
An initial assessment of the RPM Fluoro-Tool was performed to validate measurement, 
using a QUASAR TM programmable respiratory motion phantom (Modus Medical Devices, 
London, ON, Canada). QUASARTM phantom consists of a programmable stepper motor 
with a stage, an acrylic body oval, and a cylinder insert that moves in superior-inferior 
directions in the body oval. Motion of the insert is manually set using visualization of a 
gauge and synchronized with the vertical movements of the stage that surrogates chest 
wall motion with 1cm default amplitude. Tumour motion was simulated with 20mm 
peak-to-peak amplitude with cycle duration times of 4 sec, and MV-cine were acquired 
using 100 MU with the same EPID system as described above using clinical settings. The 
MV-cine collected 2.5 respiratory cycles of the moving insert. Motion was assessed using 
the  RPM-Fluoro  Tool  as  described  above  and  repeated  ten  times  in  order  to  assess 
measurement accuracy of toolkit with respect to mechanics of the phantom and the 
used MV-cine imaging procedure. An identical storage system to that used with clinical  - 87 - 
Figure 4-2. Flowchart of steps required to produce an MV cine-image. 
 
 
 
 
 
 
 
 
 
 
MV-cine exported from Aria Version 8.5 
to computer hard drive. 
MV-cine imported into ImageJ for sorting into 
chronological order on computer hard drive. 
MV-cine opened in RPM 
Fluoro Tool. 
Reference Box placed around 
internal structures using RPM 
Fluoro Tool and motion 
calculated. - 88 - 
Figure 4-3. Screen-shots of the RPM-Fluoro Tool with each of the internal structures 
highlighted  with  a  reference  box.  From  the  top;  primary  tumour,  carina  and  hilar 
structure respectively. 
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cine-images was used with an average image of every two frames (image pairs) making 
up the MV cine-image. 
 
2.  Assessment of interclinician variability in motion calculation. 
The results derived using the tool with two different users were assessed. The motion 
of  the  primary  tumour,  hilum  and  carina  were  assessed  in  6  MV-cine  by  two 
independent  observers.  A  patient  with  significant  motion  was  selected  so  that  the 
potential  for  differences  in  motion  would  be  larger.  The  two  different  motion 
measurements for each structure in each cine-image were compared to ensure the tool 
was not user dependent.  
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4.3 Results 
 
RPM-Fluoro Tool Analysis 
The  mean  peak-to-peak  amplitude  of  the  phantom  measured  from  20  imaged  full 
respiratory cycles was 19.5 mm (range 19.3 to 19.7mm). There are a number of factors 
which may affect this result. As discussed above the predefined motion of the phantom 
was manually set using a gauge that will introduce a small offset value. In addition the 
standard deviation of 0.16 mm is smaller than the pixel dimension 0.26mm at 100cm 
isocenter  level.  The  range  in  measurements  are likely  introduced  due  to  measuring 
object position from averaged image pairs, as depending on the velocity of object, the 
average image will show slightly variable blurring. Taking all these effects into account 
we felt confident the RPM-Fluoro Tool accurately measured the motion of object on 
MV-cine. 
 
The mean difference in tumour, hilar structure and carina motion between the two 
observers was 0.4mm (range 0.0 to 0.9mm), 0.6mm (0.1 to 1.0mm), 0.3mm (range 0.1 
to 0.8mm) respectively. None of the analyses demonstrated a difference in structure 
motion between observers larger than 1mm.  
 
The Clinical MV-cine Analysis 
Six patients with either stages IIIA or IIIB lung cancer were identified for the analysis, 
and tumour characteristics are summarized in Table 4-1.   
 
•  AIM 1: Identification of intrathoracic structures in treatment fields 
Each treatment plan consisted of between 5 – 10 fields. In the six patients there were a 
total of 25 fields. These 25 fields were assessed on 4 consecutive days, so in total 100 
MV-cine were assessed. 
The most commonly recognizable structure was the carina, which was situated within 
96  of  the  fields.  With  the  guidance  from  the  corresponding  digitally  reconstructed 
radiograph  (DRR),  the  carina  was  identifiable  in  80  of  the  96  MV-cine  (83%).  The 
primary tumour mass could be identified in 68 of the 100 cine-images (68%). The hilum - 91 - 
was situated in 88 fields and could be identified in 64 (73%). It is important to highlight 
that in this group of patients, 4 of the 6 patients had hilar tumours, which may have 
resulted in the hilum being more readily visible. There were 60 oblique fields. In these 
fields, the carina was visible in 80%, the tumour mass in 32% and the hilar mass in 50% 
of the fields it was situated in. 
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Table 4-1. Patient Characteristics 
 
LMZ – left mid zone. RMZ – right mid zone. RLZ – right lower zone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Tumour 
Stage 
Nodal 
Stage 
 
Primary Tumour 
maximum diameter 
(cm) 
Location 
Total Dose 
(cGy) 
Dose per 
fraction 
No of 
Fields 
               
Patient 1  T4  N3  7.2  RMZ  4500  300  5 
Patient 2  T3  N2  4.2  RMZ  6000  200  10 
Patient 3  T3  N2  7  RMZ  6600  200  5 
Patient 4  T4  N2  11  RMZ / RLZ  6000  200  7 
Patient 5  T3  N2  5.8  RMZ  5775  275  5 
Patient 6  T3  N2  7.5  LMZ  4500  300  5 - 93 - 
•  AIM 2: Factors which impaired the quality of MV cines images 
Among  the  factors  which  limited  the  ability  to  visualize  the  carina  were  a  dense 
mediastinal shadow of similar density, MLC obliterating almost the entire field and a 60 
degree dynamic wedge obliterating the field before any structures could be visualized. 
Although  the  placement  of  a  treatment  bed  bar  over  a  structure  did  not  inhibit 
identification, it prevented the assessment of structure movement. The RPM Fluoro Kit 
follows the densest object in the reference box and with an immobile treatment bed 
bar, it continuously registered no movement.  
Of the 100 cine-images, the number of breathing cycles visualized using the RPM fluoro 
tool could be assessed in 91. Respiratory motion could not be visualized in five cine 
recordings due to all the visible movement being due to heartbeat and in four cine-
images of the same field, due to the MLC taking up almost the entire field. Of these 91 
fields, 70 included at least one complete respiratory cycle (77%). The median number 
of intra-fraction respiratory cycles observed was 2 (range, 1-6). Of the 21 fields that 
did not include a whole breathing cycle, 16 had <30MU in the field, in 4 although there 
were 40MU, a 60 degree wedge obliterated the field before any assessment could be 
made. In summary, without a wedge present, any field with >30MU’s is likely to include 
an entire breathing cycle. 
 
•  AIM 3: Comparison of motion of a structure on MV cine-image versus motion on 
4DCT.  
The median 2D movement of the primary tumour was 5mm (range, 1 – 15mm) [Table 4-
2] in comparison to the median movement of the primary tumour on the 4DCT of 10mm 
(range, 7 – 15mm). The median 2D motion of the carina in all assessable fields during 
AMTD was 3mm (range, 1 – 10mm) [Table 4-3] in comparison to the median 2D motion 
measured on the 4DCT's of the same patients, which moved 7mm (range, 4- 10mm).  
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Table  4-2.  Two-dimensional  intra-fraction  tumour  motion  (mm)  during  delivery  of 
Amplitude Monitored Treatment Delivery. 
 
 
   
   
Intra-fraction Tumour Motion during Amplitude Monitored Treatment Delivery (mm) 
   
   
Fraction 1 
   
Fraction 2 
   
Fraction 3 
   
Fraction 4 
 
 
4DCT 
motion 
 
Mean  S.D. 
 
Mean  S.D. 
 
Mean  S.D. 
 
Mean  S.D. 
 
Patient 1 
 
6.9 
 
 
6.6 
 
1.8 
 
 
4.6 
 
1.0 
 
 
4.6 
 
0.8 
 
 
4.4 
 
0.8 
Patient 2  6.5    1.6  0.6    2.2  0.9    2.6  0.2    2.0  0.3 
Patient 3  7.8    9.4  3.7    6.2  2.3    9.1  0.8    7.3  2.9 
Patient 4  9.8    11.0  3.9    5.3  0.3    5.2  1.3    9.9  2.4 
Patient 5  15.0    8.7  1.6    10.0  1.4    8.9  0.1    7.4  1.0 
Patient 6  10.5    5.7  1.1    3.8  0.3    7.0  2.3    7.6  1.4 
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Table 4-3. Two-dimensional intra-fraction carina motion during delivery of Amplitude 
Monitored Treatment Delivery. 
 
 
 
 
   
   
Intra-fraction Carina Motion during Treatment Delivery 
   
   
Fraction 1 
   
Fraction 2 
   
Fraction 3 
   
Fraction 4 
 
4DCT 
motion 
 
Mean  S.D.   
Mean  S.D.   
Mean  S.D.   
Mean  S.D. 
Patient 1  3.7    2.3  0.9    2.4  1.2    2.2  0.5    1.9  0.9 
Patient 2  6.9    1.9  0.7    2.3  0.3    2.5  0.8    1.6  0.4 
Patient 3  10    6.8  2.1    5.4  1.5    6.4  1.9    4.2  1.9 
Patient 4  7.8    3.4  0.9    3.0  0.4    4.1  1.1    2.8  0.1 
Patient 5  7    3.8  3.1    3.9  0.4    2.5  0.9    4.0  3.1 
Patient 6  5.6    1.3  0.0    1.6  0.8    1.9  0.9    1.5  0.6 - 96 - 
4.3 Discussion 
 
This  study  shows  that  intrathoracic  structures  can  be  visualized  in  MV-cine  for  a 
significant  proportion  of  patients  undergoing  radiotherapy  for  stage  III  lung  cancer, 
both in AP and oblique fields. The frequency with which structures were identified was 
higher than is generally expected. This may be due to the images being cine-images 
rather than single frames as both observers noted that the identification of structures 
was significantly easier with the cine-image rather than single frames. The use of the 
BEV  also  contributed  to  a  higher  identification  rate.  This  is  similar  to  having  the 
structures  superimposed  onto  the  cine-image  which  is  routine  practice  in  other 
verification images.  
 
Factors which impair the ability to identify structures on MV images were identified and 
these  included  selection  of  dynamic  wedge  angles  above  60º,  fields  with  large 
quantities  of  MLC,  and  delivery  of  ≤30MU.  The  position  of  the  treatment  bed  bar 
limited the assessment of internal structure movement. We are continuing to collect 
data on MV-cine; these guidelines have enabled us to only image fields that will allow 
motion assessment. 
 
The use of the RPM fluoroscopy tool permits calculation of intrafraction motion of these 
internal structures. In order for MV-cine to be used as an independent verification tool, 
other motion must be assessed such as interfraction motion and set-up error. This can 
currently be assessed by superimposing structures from the planning scan onto the MV 
cine-image  and  making  manual  measurements,  however  it  is  a  time-consuming, 
complicated  process.  In  order  for  MV-cine  to  be  used  routinely  as  an  independent 
verification tool, assessing inter and intra fraction motion as well as set-up variation, 
significant software development would be required to streamline this process. As this 
was  only  an  explorative  study,  only  observations  can  be  made  on  the  analysis  of 
internal structure movement. 4DCT remains a snap shot of tumour motion and it is 
therefore reassuring to see that the majority of intrafraction motion on treatment was 
less than the motion visualized in the 4DCT. This is reassuring because if the 4DCT over - 97 - 
estimates  intrafraction  motion,  and  as  a  result  a  larger  margin  and  more  adverse 
effects  occur,  at  least  there  is  no  geographical  miss  of  the  tumour  due  to 
underestimation of tumour motion at 4DCT. One can speculate as to why intrafraction 
motion is less on treatment than during 4DCT. It is possible that patients are more 
anxious during the 4DCT as it is their first visit to the department and they are unsure 
of proceedings. This may result in a slightly increased tidal volume, increasing tumour 
motion. As they attend daily, their anxiety disappears and as a result their tidal volume 
and tumour motion. These are speculations however the reason for this fall in motion 
requires  further  investigation.  It  must  be  noted  that  in  this  study,  AMTD  may  have 
prevented unusually large respiration cycles from being treated. In centres where AMTD 
is not routinely used, this verification tool would highlight those patients with unusually 
shallow  breathing  at  4DCT  scanning,  resulting  in  a  systematic  error  due  to 
underestimation of tumour movement. It is also of interest to note that different fields 
provided different amounts of movement, indicating that analysis of motion on MV-cine 
from one field alone is not necessarily representative of all the treatment. With the 
knowledge of the factors that allow a good MV cine-image, the VUMC are continuing to 
collect  data  in  a  larger  group  of  the  lung  cancer  patients  in  order  to  draw  some 
conclusions on intra-fraction motion. 
 
Although the use of techniques such as IMRT do not support acquisition of MV-cine, such 
plans can be adapted to include at least one non-IMRT AP field which would allow the 
capture of MV images as a verification tool [137]. 
 
In conclusion, internal anatomy can be reliably identified using MV-cine of the thorax. 
This allows for residual motion to be measured during the delivery of image-guided 
radiotherapy.  Our  analysis  highlights  the  potential  of  these  images  for  use  as  an 
independent  verification  tool  but  in  order  for  quick-step  assessment  of  the  tumour 
intrafraction and interfraction motion, as well as setup variation, significant software 
development is required.  
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5.  AMPLITUDE  MONITORED  TREATMENT  DELIVERY  (AMTD):  A  RESPIRATORY-MOTION 
MANAGEMENT  TECHNIQUE  AIMED  TO  LIMIT  VARIATIONS  IN  INTRA-FRACTION  MOTION 
BETWEEN PLANNING AND TREATMENT DELIVERY. 
 
 
5.1 Introduction 
 
In patients whose tumours show significant respiration-induced motion, 4DCT identifies 
those  who  may  benefit  from  respiratory-gated  radiotherapy  (RGRT)  by  identifying 
potential windows within the respiratory cycle, for gated-delivery [87,138]. However, 
this form of RGRT is not suitable for all patients. There is a clinical benefit in only a 
minority of patients, whose tumours show significant motion [139]. In addition a regular 
respiratory cycle is required and although the reproducibility can be improved on with 
respiratory coaching [140], it remains unachievable for some patients.  
 
In order to exclude the possibility of acquiring non-representative motion data on the 
4DCT,  as  well  as  to  overcome  limitations  of  traditional  forms  of  RGRT,  the  VUMC 
implemented a novel form of respiratory management ‘Amplitude Monitored Treatment 
Delivery’  (AMTD)  which  is  illustrated  in  Figure  1-7.  This  approach  is  essentially 
respiratory gating with a larger duty-cycle, where the radiation is delivered while the 
intra-fraction surrogate motion is equal, or less, to what was recorded at 4DCT and 
automatically  withheld  when  the  intra-fraction  motion  exceeds  that  seen  at  4DCT. 
AMTD aims to limit the possibility of a geographic miss arising when a larger tumour 
amplitude occurs during treatment delivery, than what was observed in the planning 
4DCT.  
 
In  the  feasibility  study  of  MV-cine,  the  MV-cine  images  demonstrated  that  in  the 
majority of patients there was more motion on the 4DCT than on the MV-cine, which is 
preferable as it prevents geographical miss. As we have now confirmed that MV-cine 
can be used to monitor motion, and have identified the limiting factors so they can be 
avoided, we embarked on a project to verify the use of AMTD using MV-cine images. - 99 - 
The  implementation  of  the  AMTD  technique  is  described  and  MV-cine  images  were 
collected and analysed to verify the AMTD treatment.  
 
 
5.2 Materials and Methods 
 
Patient selection, image acquisition and target definition 
Data  from  twenty  consecutive  patients  who  completed  AMTD  treatment  for  node-
positive, non-small cell lung cancer at the VUMC, Amsterdam, The Netherlands, were 
retrospectively analyzed. Patients are eligible for AMTD if their primary lung tumours 
showed  limited  motion  (generally  ≤10  mm)  on  4DCT  scan,  or  if  the  tumour  motion 
exceeds  1cm  but  they  are  unable  to  maintain  a  regular  respiratory  cycle  despite 
respiratory coaching. For those patients with tumour motion ≥1.0 cm and/or when a 
reduction  in  the  volume  of  lung  tissue  receiving  threshold  doses  of  20  Gy  (V20)  is 
expected with phase gating at end-inspiration lung volume, phase-based gated delivery 
is employed. In three of the 20 patients, the maximum motion of the primary tumour 
exceeded 11 mm (13.2-13.8 mm), but the patients were unable to maintain a regular 
respiratory  cycle  hence  AMTD  treatment  was  chosen.  Patient  characteristics  are 
summarized in Table 5-1.  
 
All patients undergoing high dose thoracic radiotherapy at the VUMC undergo a single 
4DCT scan on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) during 
quiet  uncoached  respiration  as  previously  described  in  Chapter  4.2.  The  respiratory 
waveform is co-registered using the Varian Real-Time Positioning Management System 
(RPM; Varian Medical Systems, Palo Alto, CA). The 10 phases of the 4DCT were created 
and reviewed on the Advantage 4D workstation (GE Healthcare, UK). All phases where 
the tumour or lymph nodes lie in the extremes of motion were identified and used to 
create a gross tumour volume encompassing the tumour in all phases of the respiratory 
cycle on Eclipse Planning System (Varian Medical Systems, Palo Alto, CA). Subsequently, 
a margin of 5mm was added for microscopic disease and 5mm for set-up error was  
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Table 5-1. Patient characteristics. 
 
 
  
Tumour  
Stage 
Nodal  
Stage 
 
Tumour Size 
 (max. diameter  
in cm) 
Location 
Total Dose 
(cGy) 
Dose per 
fraction 
No of 
Fields 
 
Patient 1 
 
T4 
 
N3 
 
7.2 
 
RMZ 
 
4500 
 
300 
 
5 
Patient 2  T3  N2  4.2  RMZ  6000  200  10 
Patient 3  T3  N2  7  RMZ  6600  200  5 
Patient 4  T4  N2  11  RMZ / RLZ  6000  200  7 
Patient 5  T3  N2  5.8  RMZ  5775  275  5 
Patient 6  T3  N2  7.5  LMZ  4500  300  5 
Patient 7  T4  N1  7.8  LMZ  6600  200  5 
Patient 8  T4  N2  10.35  LMZ  5000  200  6 
Patient 9  T4  N2  11.8  LMZ  4500  300  6 
Patient 10  T2  N2  2.8  RMZ  6000  200  7 
Patient 11  T2  N2  5.75  RMZ  6000  200  6 
Patient 12  T2  N2  4.3  LMZ  6000  200  6 
Patient 13  T4  N3  5.7  RLZ  6000  200  5 
Patient 14  T4  N3  9.15  mediastinal  4600  200  5 
Patient 15  T3  N2  9.15  RUL  6600  200  7 
Patient 16  T3  N2  5.3  LLL  6600  200  6 
Patient 17  T4  N3  5.19  LMZ  5000  200  5 
Patient 18  T1  N2  1.8  RMZ  5000  200  7 
Patient 19  T3  N1  8.5  RUL  5000  200  4 
Patient 20  T4  N1  7.3  RUZ  6600  200  4 - 101 - 
added to create the planned target volume (PTV). All patients have treatment plans 
consisting of 5-10 fields using 6 or 15 MV photons.  
 
Treatment delivery 
Radiotherapy was delivered on a Varian 2300 C/D linear accelerator equipped with a 
120  multileaf  collimator,  (Varian  Medical  Systems,  Palo  Alto,  CA)  to  total  doses  of 
between 45Gy in pre-operative cases to 66Gy in radical cases, in fractions of 2-3Gy.  
 
During treatment delivery, no form of respiratory coaching was undertaken as a regular 
wavelength and amplitude are not required for AMTD treatment. Patient positioning 
was performed using laser beams and either an orthogonal pair of kV images, taken in 
the  anterior-posterior  and  lateral  position,  or  kV  cone-beam  CT  (CBCT)  images.  An 
online bony match was performed followed by a shift to eliminate the disparities. The 
original  volumes  are  superimposed  on  the  images  and  a  visual  check  was  made  to 
ensure the tumour lay within the GTV. The RPM system was used to record a respiratory 
waveform. On each treatment day, the end-expiration position of the respiratory trace 
was programmed as the baseline for the amplitude threshold. The maximum amplitude 
of the respiratory trace observed at the time of 4DCT was specified as the maximum 
acceptable  respiratory  trace  amplitude  during  treatment.  During  delivery,  if  the 
respiratory trace amplitude exceeded the maximum acceptable amplitude, the linac 
was  programmed  to  automatically  turn  off.  Once  the  respiratory  trace  fell  back 
between these points, irradiation was resumed. 
 
Intra-fractional image acquisition 
The acquisition of MV-cine is identical to that described in section 4.2 with a step by 
step illustration of the steps involved in the production of MV-cine in Figure 4-2.  
 
During  all  clinical  MV-cine  acquisition  procedures,  clinical  beam  parameter  settings 
were  used  (6  MV  photon  energy;  dose  rate  setting  600  MU/min).  MV-cine  imaging 
supports fast image capture of 7-8 image frames per second. The beams that would 
give the best image quality were selected by using fields closest to gantry angles 0 or - 102 - 
180  degrees,  with  large  dimensions,  large  numbers  of  monitor  units  and  minimal 
wedges. For storage purposes every two frames were saved as an average frame. This 
prevented overload of the hard drive on which the images were saved. 
Six  MV-cine  from  different  fractions  were  randomly  selected  and  analysed  for  each 
patient.  Initially  they  were  exported,  in  DICOM  format  from  the  patient  data  base 
system (ARIA Version 8.5, Varian Medical Systems, Palo Alto, CA) to an independent 
station’s hard-drive. Software developed in-house for the ImageJ program was used to 
resolve the time order for DICOM-based images in exported stacks. ImageJ is a Java-
based image processing package (http://rsb.info.nih.gov/ij/) that was run under the 
Windows XP operating system on a Pentium 4 processor with 2 GB on board access 
memory.  
 
The number of available respiratory cycles captured in each MV cine-study was noted.  
 
Assessment of 4DCT Motion  
For the purposes of this study, the 4DCT motion of the tumour, hilum and carina was 
measured  at  an  Advantage  4D  workstation  (GE  Healthcare,  UK)  by  a  clinician.  The 
maximum 2D movement of all three internal structures was measured in the coronal 
view of the movie with the straight line measuring device. When assessing tumour and 
hilar structures, the motion measurements were taken for the apex, the inferior border 
and  the  lateral  edge  of  the  structures.  The  maximum  movement  was  noted  as  the 
largest of the three measurements.  
 
Assessment of motion during AMTD 
Each  MV  cine-image  was  reviewed  using  the  RPM-Fluoro  Tool  as  described  above. 
Following the calculation of motion of each internal structure, the MV cine-image was 
reviewed  with  the  reference  box  moving  in  tandem  with  the  internal  structure,  to 
ensure  the  reference  box  encompassed  the  internal  structure  throughout  the 
respiratory cycle. If the reference box did not follow the internal structure well, the 
process  was  repeated.  The  motion  was  noted  when  the  internal  structure  and  the 
reference box moved together coherently. - 103 - 
5.3 Results 
 
Clinical Analysis 
Tumour characteristics of all 20 patients are summarized in Table 5-1. Six MV-cine were 
analyzed for each patient. Both observers identified images of the primary tumour in 
95% of cases, although it must be noted that 12/20 patients (60%) had primary hilar 
tumours. Separate hilar structures were identified in the other 40% of patients with a 
primary tumour located elsewhere. Of these, only 88% had hilar structures that were 
consistently identifiable by both observers. The carina was visible in 95% of MV-cine. 
The mean number of respiratory cycles in all 120 MV-cine was 2.45 cycles (range 1 to 
6), as assessed by peak-to-peak amplitudes, allowing for tumour amplitude assessment 
in all the MV-cine.  
 
In 19 patients, the 2D superior-inferior primary tumour movement was calculated on 
the 4DCT. Motion of the primary tumour was not assessed for a primary mediastinal 
tumour. The mean motion of the primary tumour on 4DCT was at 7.3mm (range 2mm to 
13.8mm). Of those 7 patients without hilar tumours, the mean movement of the hilar 
structure  was  11.0mm  (range  4.2mm  to  15.1mm).  The  mean  carina  movement  was 
calculated  from  measurements  from  all  patients  and  was  6.8mm  (range  1.8mm  to 
21.2mm). 
 
Tables 5-2, 5-3 and 5-4 demonstrates the tumour, hilar structure and carina motion 
seen  on  the  MV-cine    of  each  patient  respectively  in  comparison  to  the  internal 
structure motion seen at 4DCT. A total of 6 MV-cine were studied per patient. Mean 
motion of primary tumour, carina and hilum on 4DCT was at 7.3mm (range 2-13.8mm); 
6.8mm  (1.8-21.2mm)  and  11.0mm  (4.2-15.1mm)  respectively.  Corresponding  motion 
during  AMTD  was  4.1mm  (0.6-13.6mm);  2.7mm  (0-10mm)  and  6.0mm  (1.8-14.4mm), 
respectively.  
 
The tumour and the hilar structures were tracked well by the RPM-Fluoro Tool. The 
carina often had areas of the treatment bed or a vertebrae in the field, all which make - 104 - 
tracking impossible as the reference box follows the immobile high dense structure, 
hence only 34%, (39 from 114) of the MV-cine  with visible carina's could be tracked. 
 
The  number  of  studies  in  which  the  primary  tumour  motion  on  an  MV  cine-image 
exceeded  that  on  the  corresponding  4DCT  was  16  of  the  114  (14%)  cine-images. 
Interestingly, nearly all were acquired from Patients 1 and 2, indicating a systematic 
error in 10% of patients. The remaining MV-cine demonstrating more motion than the 
4DCT, were sporadically distributed between all the other patients and hence are likely 
to represent random errors.  
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Table 5-2. Primary tumour motion on 4DCT and during AMTD treatment. 
 
   
 
4DCT Tumour 
Motion 
(mm) 
  MV cine-image Tumour Motion (mm) 
       
 
Mean 
 
 
S.D. 
 
 
Min 
 
 
Max 
Patient 1    5.9    8.2    3.2    4.5    12.8 
Patient 2    2.0    3.9    1.5    2.0    6.3 
Patient 3    6.9    3.8    0.9    2.9    5.1 
Patient 4    10.5    6.9    1.6    5.0    8.9 
Patient 5    9.8    7.6    2.8    4.6    12.6 
Patient 6    7.8    2.1    0.3    1.7    2.4 
Patient 7    6.4    2.5    0.4    2.0    2.9 
Patient 8    4.9    2.6    0.6    1.7    3.3 
Patient 9    5.4    0.9    0.2    0.6    1.1 
Patient 10    7.6    4.7    2.1    2.0    7.8 
Patient 11    3.0    1.9    0.8    1.2    3.5 
Patient 12    13.2    9.0    3.7    5.0    13.6 
Patient 13    Mediastinal tumour therefore analysis not undertaken 
Patient 14    13.4    4.2    1.2    2.3    5.8 
Patient 15    8.3    3.4    1.3    2.0    5.1 
Patient 16    4.9    4.3    1.5    2.2    6.4 
Patient 17    13.8    5.1    1.1    3.5    6.5 
Patient 18    5.9    2.7    0.9    1.7    4.3 
Patient 19    3.4    0.8    0.2    0.6    1.0 
Patient 20    6.9    2.6    1.0    1.6    4.4 
 - 106 - 
Table 5-3. Hilar Structure motion on 4DCT and during AMTD treatment. 
 
 
 
   
 
4DCT Hilar 
Motion 
  MV cine-image Hilar Structure Motion (mm) 
    (mm)    Mean    S.D.    Min    Max 
Patient 1    15.1    10.9    2.8    6.1    14.4 
Patient 2    15.0    7.8    2.3    5.2    11.5 
Patient 10    8.1    8.1    3.0    4.7    11.7 
Patient 11    12.8    2.1    0.2    1.8    2.3 
Patient 12    9.9    6.3    3.3    2.3    10.5 
Patient 15    11.8    4.6    1.5    3.2    7.3 
Patient 19    4.2    2.4    0.5    1.8    2.8 
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Table 5-4. Carina motion on 4DCT and during AMTD treatment. 
 
 
 
 
   
 
4DCT Carina 
Motion 
  MV cine-image Carina Motion (mm) 
    (mm)    Mean    S.D.    Min    Max 
Patient 1    7.0    2.2    0.5    1.5    2.6 
Patient 2    10.0    5.7    1.6    4.0    8.3 
Patient 3    5.6    Cannot see carina 
Patient 4    3.7    0.9    0.3    0.6    1.2 
Patient 5    7.8    2.9    1.0    2.0    4.4 
Patient 6    6.9    2.0    0.8    1.4    3.1 
Patient 7    7.3    2.0    0.0    2.0    2.0 
Patient 8    5.4    1.2    0.5    0.6    2.0 
Patient 9    4.2    1.1    0.0    1.1    1.1 
Patient 10    6.0    3.1    1.3    2.2    4.0 
Patient 11    4.4    2.4    1.5    0.6    4.5 
Patient 12    4.9    2.6    2.1    0.0    5.1 
Patient 13    4.4    4.2    1.7    2.2    7.2 
Patient 14    4.7    2.0    0.9    1.0    3.5 
Patient 15    8.9    5.8    2.7    1.6    9.1 
Patient 16    6.9    RPM-Fluoro Tool failed to track carina 
Patient 17    8.6    5.1    4.3    2.3    10.0 
Patient 18    6.9    2.3    2.5    1.0    7.5 
Patient 19    1.8    1.2    0.6    0.6    2.0 
Patient 20    21.2    RPM-Fluoro Tool failed to track carina - 108 - 
5.4 Discussion 
 
Our  study  highlights  the  importance  of  independently  verifying  novel  radiotherapy 
techniques.  We  used  MV-cine  to  study  intra-fraction  motion;  an  approach  has  been 
reported to be a feasible and clinically effective method of independent verification 
[141,142,143]. The quality of MV-cines is supported by the fact that tumour and carina 
were visualized in 95% of all analyzed images, and the hilum in 88%. In cases where the 
primary  tumour  is  not  visualized,  the  carina  and  the  hilar  structure  can  act  as 
surrogates for tumour motion [126]. In 34% of MV-cines, difficulties were observed in 
tracking the carina, mainly due to the bed frame in the field. The latter was solved by 
repositioning the former out with the field for future fractions. Use of MV-cines were 
not possible using conventional IMRT plans, but hybrid IMRT plans that use at least one 
non-IMRT  anterior  field  would  allow  an  MV  cine-image  for  independent  verification 
[144].   
 
The motion demonstrated in this group of locally advanced tumours can be compared 
to that of Liu et al [145]. Liu et al assessed the motion of 166 locally advanced tumours 
and found that the population averages of tumour motion were 0.50cm in the superior-
inferior  in  comparison  to  our  mean  motion  of  0.74cm  on  4DCT.  They  noted  the 
percentage of patients with >0.5cm of motion as 39.2% and >1.0cm of motion as 10.8% 
respectively. In our series the tumours moved more with motion >0.5cm and >1.0cm in 
74% and 21%. The slightly larger motion seen in our series, may be in part due to a 
smaller sample size however despite this, it is unexpected, as those with large motion 
who were suitable for RGRT were excluded.  
 
AMTD  appears  to  be  a  suitable  approach  for  the  majority  of  patients  who  are  not 
candidates for traditional RGRT due to limited tumour motion, irregular breathing or 
intolerance  of  coaching.  It  does  not  require  mandatory  respiratory  coaching,  as 
maintaining a reproducible wavelength and amplitude is not integral to delivery, and is 
more efficient than traditional RGRT as the duty-cycle is larger. With AMTD delivery, - 109 - 
only 10% of patients have consistently more intra-fraction tumour motion on treatment 
than at 4DCT.  
 
The  AMTD  technique  is  not  without  limitations.  Although  correlation  coefficients 
between tumour and external surrogates have been reported to be as high as 87% in the 
superior-inferior direction [85] and 81% in all directions [88], little or no correlation is 
seen in a minority of patients. It requires further study to investigate whether the 10% 
of patients with consistently larger intra-fraction tumour motion on during treatment 
are those with little or no correlation. If a lack of correlation is the cause of the larger 
intra-fraction  motion,  new  software  tools  are  available  to  assess  the  correlation 
between external surrogate and internal motion prior to treatment to identify those in 
whom AMTD is not applicable [146]. If there is an alternative explanation this study 
offers  a  simple,  radiation  free  method  of  identifying  them  with  use  of  MV-cines, 
although  improved  software  would  be  required  as  the  current  process  is  time-
consuming and not feasible for routine clinical use. The alternative imaging techniques 
that can be used on-line to assess intra-fraction motion are fluoroscopy [49,147] or 4D-
CBCT [65], however the disadvantages of these include the additional radiation dose 
and treatment time. Also, the intra-fraction motion seen during online imaging does 
not  necessarily  represent  the  motion  during  treatment,  only  prior  to  treatment,  at 
which time the patient may be breathing differently for a variety of reasons including 
anxiety due to the gantry rotating or additional noise.  
A further limitation of AMTD is the lack of assessment of baseline shifts. Our current 
technique of online CBCT, utilizes the fact a CBCT is taken over a number of respiratory 
cycles, hence creating an image demonstrating the tumour in the mean position. The 
visual  check  comparing  the  tumour  on  the  CBCT  to  the  planning  gross  tumour 
throughout the respiratory cycle highlights any obvious baseline shift in mean position 
of the tumour. The MV-cine could potentially be used to make a comment on baseline 
position  however  due  to  lack  of  integration  into  the  planning  and  delivery  system, 
software limitations make it is impossible to confidently comment on baseline shift at 
present. 4D-CBCT is currently the gold standard for online assessment of baseline shift, 
however the limitations are noted above.  - 110 - 
There may be concerns that AMTD requires additional time for treatment delivery due 
to steps such as placement of an infrared marker box, assessment of the respiratory 
waveform, and the intermittent treatment beam. However our treatment slots have 
not increased with the introduction of AMTD and the 15 minute treatment slots are 
identical to non-AMTD thoracic treatments.  
 
AMTD  offers  a  novel  method  of  limiting  variation  in  intra-fraction  motion  and  is 
applicable  to  the  majority  who  are  not  suitable  for  traditional  forms  of  RGRT.  Our 
findings also add to the growing body of data showing the potential of MV-cine as a 
verification tool in the delivery of thoracic radiotherapy. - 111 - 
6.  INVESTIGATION  OF  THE  CLINICAL  BENEFIT  OF  RESPIRATORY  GATED 
RADIOTHERAPY (RGRT) IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC). 
 
 
6.1 Introduction 
 
Traditional forms of RGRT such as phase-based or amplitude-based RGRT, have been 
shown to reduce the size of the PTV when compared to the standard 4D PTV [91]. The 
theoretical  advantages  are:  reduction  in  toxicity;  potential  for  dose  escalation;  and 
fewer  patients  having  radical  treatment  withheld  on  account  of  large  volumes  or 
unacceptable toxicity parameters.  
 
Despite the enthusiasm regarding this new technique, it is essential to be aware of the 
potential disadvantages which are discussed in detail in section 1.3.4.1.  
 
In view of these concerns and controversies, it is imperative to quantify the clinical 
benefit  to  patients  that  RGRT  provides,  when  compared  to  continuous  (non-gated) 
4DCT treatment to save embarking unnecessarily on complex and costly techniques. As 
yet, there are no randomised clinical trials and only one paper suggesting there is a 
reduction in lung V20 with RGRT [91]. There is no consensus on which parameters can 
predict  an  improvement  in  clinical  outcome  when  comparing  RGRT  to  continuous 
irradiation of 4DCT; however the toxicity parameters that are routinely used in clinical 
practice can be used as surrogates. These include the volume of lung receiving 20Gy 
(V20 lung); volume of lung receiving 5 Gy (V5 lung); mean lung dose (MLD); and volume 
of  oesophagus  receiving  50Gy  (V50  oes).  As  there  is  no  consensus  on  the  best  lung 
parameters,  a  number  of  different  parameters  were  used  that  have  all  been 
demonstrated  to  correlate  with  radiation  pneumonitis  [148,149,150].  There  is  no 
consensus on the toxicity parameter to be used with the oesophagous, some use the 
length of oesphagous irradiated others the V50 or V55. V50 was selected as a recent - 112 - 
study of 100 patients assessing different dosimetric parameters that identified this as 
the one that best correlated with toxicity [151]. If the toxicity parameters are reduced 
with RGRT in comparison to continuous (non-gated) 4DCT treatment, three theoretical 
benefits of RGRT could be achieved: toxicity will decrease; there is potential for dose 
escalation; and more patients would have toxicity parameters within the acceptable 
levels to proceed to radical radiotherapy. 
 
There were four aims of this study (1) quantify the improvement in clinical outcome of 
RGRT  in  comparison  to  continuous  (non-gated)  4DCT  irradiation,  by  using  toxicity 
parameters  as  surrogates  for  clinical  outcome;  (2)  assess  the  correlation  between 
tumour motion and benefit of RGRT with a view to identifying a threshold of tumour 
motion where RGRT should be considered; (3) compare the benefit of inspiration RGRT 
to expiration RGRT; (4) assess the benefit of RGRT when smaller set-up margins (CITV 
to PTV margin) are used.  
 
 
6.2 Materials and Methods 
 
Patient Data Acquisition. 
CT image datasets of consecutive node-positive lung cancer patients were reviewed 
retrospectively. These patients had previously undergone 4DCT for treatment planning 
and  completed  routine  radical  radiation  to  a  dose  of  55Gy  in  20  fractions  with 
continuous (non-gated) 4DCT treatment. In order to select patients for the study, an 
assessment  of  tumour  motion  was  undertaken  using  the  cine-movie  facility  on  an 
Advantage 4D workstation (GE Healthcare, UK). The maximum distance the apex and 
inferior border of the primary tumour moved during the respiration cycle was measured 
using the straight line measuring device. Any patient with >5mm craniocaudal tumour 
movement  at  either  of  these  points  was  eligible.  Fifteen  consecutive  patients  were 
selected. 
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The 4DCT image acquisition has been reported in detail in Section 2-2. In brief, patients 
were scanned on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) with 
scanning parameters set at 120 kV, 20mA with a slice thickness of 2.5mm. Patients 
were  audio-coached,  with  the  rate  of  respiration  set  at  their  initially  recorded 
respiratory rate. The RPM System is used to record a trace of the patient’s respiratory 
cycle during acquisition of the scan. In each couch position, the scanner acquired 10 
consecutive  scans  over  the  course  of  one  breathing  cycle.  These  scans  were  sorted 
using the Advantage 4D workstation into 10 phase-bins representing the 10 phases of 
the respiratory cycle. 
 
 
Delineation of Targets. 
The  author  delineated  3  different  GITVs  for  each  patient  using  Varian  Eclipse 
Treatment Planning System, software version 8.6 (Varian Medical Systems, Palo Alto, 
CA).  The  different  GITVs  were  created  to  represent,  the  full  extent  of  respiratory 
motion, end-inspiration and end-expiration. 
 
To delineate the GITV for gating in end-expiration, Exp_GITV, the cine movie of all 
phase-bins was reviewed. The Exp_GITV was delineated using the phase-bin with the 
tumour  in  the  most  superior  position.  The  Exp_GITV  was  then  reviewed  in  the 
surrounding 2 phase-bins and enlarged to encompass any additional tumour visualised. 
This additional tumour visualised represents tumour movement during the imaging of 
the 3 expiratory “bins”. The GITV for gating in end-inspiration, Insp_GITV, was created 
in the same way however this time identifying the phase-bin with the tumour in the 
most inferior position and the surrounding 2 phase-bins. A composite of Exp_GITV and 
Insp_GITV was created to represent the positional variation of the tumour throughout 
all  phases  of  respiration  (4D_GITV).  A  margin  of  5mm  was  added  to  encompass 
microscopic  invasion  to  each  of  these  GITVs  and  then  two  different  planned  target 
volumes (PTV) for each GITV were created using set-up margins of 5mm and 10mm 
respectively. This created 6 different PTVs: - 114 - 
•  4D_PTV  (10mm  margin)  –  4D_GITV  with  a  5mm  for  microscopic  spread  and 
10mm set-up margin. 
•  Insp_PTV (10mm margin) – Insp_GITV with a 5mm for microscopic spread and 
10mm set-up margin. 
•  Exp_PTV (10mm margin) - Exp_GITV with a 5mm for microscopic spread and 
10mm set-up margin. 
•  4D_PTV (5mm margin) - 4D_GITV with a 5mm for microscopic spread and 5mm 
set-up margin. 
•  Insp_PTV (5mm margin) Insp_GITV with a 5mm for microscopic spread and 5mm 
set-up margin. 
•  Exp_PTV  (5mm  margin)  -  Exp_GITV  with  a  5mm  for  microscopic  spread  and 
5mm set-up margin. 
 
Organs at Risk Delineation and Treatment planning.  
The  two  4D_PTVs  had  the  dose  calculation  undertaken  on  an  Average  Intensity 
Projection (Ave-IP) data-set, created using all ten phase-bins. The two Insp_PTVs were 
calculated on an Ave-IP data-set created using the three phase-bins representing end-
inspiration and the two Exp_PTVs were calculated on an Ave-IP data-set created using 
the three end-expiration phase-bins. The whole lung was delineated on each of the 
different Ave-IPs using automatic segmentation followed by manual editing if required. 
To  calculate  the  lung  toxicity  parameters  the  whole  lung  of  the  appropriate  Ave-IP 
minus the relevant PTV was used in each plan. The oesophagus was delineated from the 
oropharynx to the oesophageo-gastic junction. 
 
Six treatment plans were generated for each patient by the author. All plans consisted 
of 55Gy in 20 fractions delivered using 3-5, 6MV photon beams with 100% prescribed to 
isocentre.    For  each  patient,  an  initial  plan  was  created  for  the  4D_PTV.  Most 
treatments  used  beams  at  gantry  angles  of  0,  60-70  and  120-130  degrees  from  the 
vertical. Additional boost fields were used to boost the periphery of the PTV where 
necessary.  The  plan  was  optimized  to  cover  as  much  of  the  PTV  as  possible  with 
between  95%  and  107%  of  the prescribed  dose,  maintaining  the  dose  to  spinal  cord - 115 - 
below 42Gy and the V20 as low as possible, as is routine in our clinical practice. The 
same beams were then applied to the other 5 PTVs. Small adjustments were made to 
beam size, gantry angle, wedge and beam weight where necessary to optimise these 
plans to the same standards.   
 
Data Analysis 
Cranio-caudal  tumour  motion  was  set  as  the  cranio-caudal  difference  between 
geometric centre positions of the GTVs in the single phase-bins representing the most 
superior and most inferior tumour positions. 
 
The volumes of the PTVs and the toxicity parameters V20 lung, V5 lung, MLD and V50 
oes were noted in all six plans for each patient. The reductions in volumes and toxicity 
parameters  between  the  4DCT  and  the  two  RGRT  plans  with  corresponding  set-up 
margins were calculated. The correlation coefficient between the reduction in toxicity 
parameters and tumour movement was calculated using Pearson’s product correlation 
coefficient  on  Microsoft  Excel  2002.  The  two-tailed  t-test  was  used  to  check  for 
statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Results - 116 - 
 
Fifteen  patients,  with  node  positive  lung  cancer  were  identified  with  >5mm  of 
movement  on  the  4DCT  planning  scan.  Tumour  staging,  location,  cranio-caudal 
movement for all patients along with PTV, V20 and MLD from 4D_PTV (10mm margin) 
are  presented  in  Table  6-1.  In  the  pre-selection  cine-movie  process  all  patients 
demonstrated  >5mm  of  movement  in  the  primary  tumour,  but  some  of  the  cranio-
caudal movements noted using the geometric centre of the entire gross tumour were 
<5mm. This is mostly due to the incorporation in the GITV of the lymph nodes which 
move less than the primary tumour.  
 Dose and volume statistics are presented in Table 6-2. In the plans created using the 
margin of 10mm, the PTV delineated for inspiration RGRT [Insp_PTV (10mm margin)] 
and  expiration  RGRT  [Exp_PTV  (10mm  margin)]  were  compared  to  the  plan  created 
using  all  phases  of  the  respiration  cycle  [4D_PTV  (10mm  margin)].  The  median 
reduction in V20 with inspiratory gating and expiratory gating was 2.0% (range 0.7% – 
3.9%) and 0.6% (range -1.1% to 4.7%) respectively; the reduction in V5 was 3.8% (range 
1.3% to 8.0%) and 1.0% (range -2.6% to 6.4%) respectively and the reduction in MLD was 
0.9Gy (range 0.2Gy to 3.2Gy) and 0.7Gy (range -0.1Gy to 2.7Gy) respectively.  
Similarly, with only a 5mm set-up margin, median reduction in V20 with inspiratory 
gating and expiratory gating was 2.4% (range 0.5% to 4.4%) and 0.5% (range -0.7% to 
3.6%) respectively; the reduction in V5 was 4.9% (range 1.2% to 8.7%) and 1.3% (range -
0.9% to 6.2%) respectively and the MLD reduction was 0.9Gy (range -0.1Gy to 3.9Gy) 
and 0.7Gy (range -0.5Gy to 3.2Gy) respectively. 
 
Figure 6-1 allows easy visualisation in scatter plots of the lack of correlation between 
the  cranio-caudal  tumour  movement  and  both  V20  and  MLD.  Table  6-3  shows  the 
correlation coefficients between tumour motion and each toxicity parameter. The only 
toxicity  parameter  that  showed  a  statistically  significant  correlation  was  between 
tumour motion and V5 in both the inspiration plans. All the other toxicity parameters of 
the lung showed no correlation.  
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The V50 oes is reduced by a mean of 2.1% (range 0% - 9.33%), 1.4% (range 0% - 9.0%) 
with  inspiration  and  expiration  RGRT  using  10mm  margins  respectively.  With  the 
margins of 5mm the inspiration and expiration margin reduction was 1.6% (range 0% - 
6.6%),  1.0%  (range  0%  -  4.6%)  respectively.  The  correlation  between  motion  and 
reduction  in  V50  oes  is  a  statistically  significantly  negative  correlation  in  both  the 
inspiration and expiration plans with the smaller margin, and fails to demonstrate any 
correlation in both 10mm margin plans, indicating that it is not the case that increased 
motion results in larger reduction in oesophageal toxicity.  
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Figure 6-1. Correlations between reduction in lung toxicity parameters and tumour 
motion in: (a) Insp PTV (10mm margin) (b) Exp PTV (10mm margin) (c) Insp PTV (5mm 
margin) (d) Exp PTV (5mm margin). 
 
(a) 
 
 
             
(b)   
   
     
 
(c) 
 
 
     
(d) 
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An additional observation of our study was that the reduction in toxicity parameters 
achieved by reducing the set-up margin, from 10mm to 5mm, during continuous (non-
gated) 4DCT treatment was actually larger than that seen with the addition of RGRT. 
This suggests that if a centre wished to reduce toxicities, there is more benefit to be 
gained by improved online verification which can reduce margins from 10mm to 5mm 
than introducing RGRT which is a complicated, work intensive technique that is only 
suitable for a minority of patients. Table 6-4 demonstrates the reduction of toxicity 
parameters when the margin is reduced versus the reduction when end-inspiration 
RGRT is used. - 120 - 
Table 6-1. Patient characteristics 
 
 
 
 
 
 
 
 
  
  
Tumour 
Stage 
Tumour 
Position 
Tumour Motion 
(cm) 
4D PTV [10mm 
margin] (cm3) 
V20 lung 
(%)  MLD(Gy) 
  
   Patient 1  T4 N2  LLL  0.62  664.56  41.8  21.7    
   Patient 2  T2 N1  RML  1.47  359.10  18.0  10.2    
   Patient 3  T2 N1  RUL  0.34  331.09  16.7  10.8    
   Patient 4  T2 N1  RML  0.75  230.99  20.1  11.6    
   Patient 5  T2 N1  RML  0.17  588.92  48.0  25.0    
   Patient 6   T1 N2  LUL  0.69  615.54  28.3  14.8    
   Patient 7  T2 N1  RLL  2.08  1323.71  28.0  18.0    
   Patient 8  T4 N1  RLL  0.67  425.97  21.5  11.8    
   Patient 9  T2 N2  RUL  2.83  770.88  31.7  17.4    
   Patient 10  T2 N2  RLL  0.23  527.85  42.4  21.6    
   Patient 11  T3 N2  RUL  0.51  163.48  13.3  7.1    
   Patient 12  T2 N1  RML  1.12  197.01  22.9  12.4    
   Patient 13  T2 N1  RLL  1.23  818.79  20.9  12.6    
   Patient 14  T3 N1  RLL  0.35  573.28  31.3  16.8    
   Patient 15  T4 N2  RML  0.96  903.00  43.7  23.6    
                 
            
Abbreviations: R, right; L, left; LL, lower lobe; UL, upper lobe; ML, middle lobe; PTV, planned target volume; 
V20, volume of lung receiving >20Gy; MLD, mean lung dose. 
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Table 6-2. Reductions of volume and toxicity parameters using RGRT compared with 
continuous (non-gated) 4DCT treatment. 
 
 
 
 
 
 
      PTV (cm
3)     V20 Lung (%)     V5 Lung (%)     MLD (Gy)    
 
V50 
oesophagus 
(%) 
 
Mean  86.40    2.05    3.95    1.09    2.09 
SD  65.60    0.92    1.84    0.71    2.84 
Insp PTV  
(10mm 
margin) 
Range  16.58 - 242.15    0.72 - 3.86    1.29 - 8.00    0.22 - 3.20    0 - 9.33 
Mean  106.04    0.58    1.25    0.87    1.36 
SD  111.61    1.43    2.11    0.68    2.42 
Exp PTV  
(10mm 
margin)  Range  26.78 - 460.62    -1.1 - 4.74    -2.59 - 6.44    -0.1 – 2.7    0 - 9.03 
Mean  69.39    2.26    4.25    1.17    1.61 
SD  56.07    1.20    2.16    0.95    2.22 
Insp PTV  
(5mm 
margin)  Range  11.61 - 213.21    0.5 - 4.4    1.21 - 8.73    0.1 – 3.9    0 - 6.6 
Mean  83.21    0.70    1.63    0.97    1.03 
SD  92.34    1.10    1.83    0.53    1.38 
Exp PTV  
(5mm 
margin) 
Range  17.71 - 384.43     -0.68 - 3.61     -0.9 - 6.23     -0.1 – 2.3     0 - 4.6 
  
Abbreviations: SD, standard deviation; MLD, mean lung dose; PTV, planned target volume; Insp PTV, PTV created at Inspiration 
RGRT; Exp PTV, PTV created at Expiration RGRT. 
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Table 6-3. The correlation between tumour motion and toxicity parameters. 
 
 
 
 
 
         V20 Lung (%)    
V5 Lung 
(%) 
  
MLD 
(Gy) 
  
 
V50 oesophagus 
(%) 
  
  
 
Correlation between tumour 
motion and Insp PTV (10mm 
margin) 
 
  -0.06    0.60*    0.34    -0.37    
  
Correlation between tumour 
motion and Exp PTV (10mm 
margin) 
  -0.41    0.29    -0.06    -0.39    
  
 
Correlation between tumour 
motion and Insp PTV (5mm 
margin) 
 
  0.15    0.59*    0.43    -0.57*    
  
Correlation between tumour 
motion and Exp PTV (5mm 
margin) 
  -0.15    0.44    0.12    -0.57*    
 
                   
  
* Indicates correlation is statistically significant with p = <0.05 
 
Abbreviations: V20, volume of lung receiving >20Gy; V5, volume of lung receiving >5Gy; MLD, mean lung dose; PTV, 
planned target volume; Insp PTV, PTV created at Inspiration RGRT; Exp PTV, PTV created at Expiration RGRT. 
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Table 6-4. Reductions of volume and toxicity parameters with the use of RGRT versus 
the reduction of set-up margins. 
 
 
 
     
 
PTV (cm
3) 
 
V20 Lung (%) 
 
V5 Lung (%) 
 
MLD (Gy) 
 
V50 oesophagous 
(%) 
 
Mean  171.93  2.81  4.95  1.59  4.05 
SD  78.79  1.83  1.71  0.63  3.83 
 
Reduction in toxicity 
parameters from:  
 
4D_PTV (10mm margin)  
to 
4D_PTV (5mm margin) 
 
Range  73.9 - 357.8  -0.1 - 6.3  1.1 - 7.8  0.8 – 3.0  0.0 - 12.6 
Mean  86.40  2.05  3.95  1.09  2.09 
SD  65.60  0.92  1.84  0.71  2.84 
 
Reduction in toxicity 
parameters from: 
 
4D_PTV (10mm margin) 
to 
Insp_PTV (10mm margin)  
 
Range  16.6 - 242.2  0.72 - 3.86  1.29 - 8.00  0.22 – 3.20  0.00 - 9.33 - 124 - 
6.3 Discussion 
 
With all the interest there is in RGRT and its implementation, it is a significant finding 
that  we  have  demonstrated  a  very  limited  improvement  of  lung  and  oesophageal 
toxicity parameters with the use of RGRT in node positive lung tumours. There are 
numerous papers addressing the likelihood of radiation pneumonitis and thereafter long 
term  lung  damage,  and  equally  as  many  papers  calculating  methods  of  predicting 
these,  however  there  remains  no  consensus  on  what  reduction  of  lung  toxicity 
parameters,  provides  what  reduction  in  likelihood  of  radiation  pneumonitis 
[143,144,145]. To quantify the reduction in risk, we would need to select a paper at 
random and calculate this risk reduction using their NTCP models, for each individual 
patient, using each different plan. However there are widely felt concerns regarding 
the use of these models for an individual patient and therefore they must be used with 
caution  [152].  Due  to  the  lack  of  consensus  on  which  model  should  be  used,  the 
concerns  regarding  these  models  in  individual  patients  and  the  large  quantities  of 
further  work  required  to  calculate  a  model  driven  reduction  of  risk  of  radiation 
pneumonitis for each patient, this analysis was not carried out. Some might argue that 
any improvement in toxicity parameters is a step in the right direction. For example, in 
our  centre,  radical  radiotherapy  is  withheld  for  patients  with  a  lung  V20  of  35% 
however individual clinicians may have different limiting parameters both in our centre 
and in other centres. In some patients, a small reduction from above to below the 
believed cut off may render a patient radically treatable within the strict confines of a 
protocol. However, out with the rigid limitations of protocols, one has to be sceptical 
whether a reduction in V20 of around 2% will reflect in a better clinical outcome for 
any  patient.  We  feel  that  this  is  outweighed  by  additional  potential  errors  and  the 
significant  additional  time  involved  in  implementation  and  treatment  with  RGRT.  In 
view of the limited reduction in toxicity parameters, it is unlikely any of the three 
theoretical advantages of RGRT will be achieved.  
 
The  challenge  is  to  identify  the  minority  of  patients  who  would  receive  the  most 
benefit from RGRT. Only one of the 15 patients (6%) had a reduction of V50 lung of >4% - 125 - 
and MLD of >4Gy. However we found no convincing correlation between tumour motion 
and toxicity parameters indicating that tumour motion cannot be used as a method of 
identification.  This  suggests  that  there  is  a  complex  combination  of  factors  which 
determines treatment toxicity parameters e.g. tumour size, tumour location (extension 
into lung or solid tissue), tumour motion, treatment beam configuration and relative 
dose weighting per beam. Further investigation is required, to see whether it is possible 
to pre-select patients for RGRT. Failing that, comparative planning will be required on 
a patient by patient basis.  
 
There are two papers investigating this issue. Starkschall et al. found that only in small 
tumours (volume of GTV <100cm3) was there a correlation between tumour motion and 
improvement in V20 [91]. Direct comparison with our results is difficult for a variety of 
reasons: they reported the V20 reduction only as a ratio, and not with any absolute 
values;  they  only  investigated  end-expiration  RGRT,  which  we  found  to  be  of  less 
benefit;  they  used  the  same  free-breathing  scan  for  dose  calculation  of  all  plans; 
thirteen of their 20 patients had GTVs of <100cm3, which are likely to represent Stage I 
tumours, of which we had none due to deliberately omitting them, the reasons for 
which  are  discussed  below.  An  additional  difference  is  the  planning  techniques. 
Starkschall et al. based their analysis on a prescription of 60Gy to the 93% isodose. 
Treatment was with a 4 field technique. AP-PA fields were weighted to deliver 44Gy 
and  lateral  or  lateral-oblique  opposing  fields  delivered  16Gy.  This  creates  a  very 
different dose distribution than our 3-field technique. In their technique, lung tissue 
which lies only within the lateral fields cannot reach a dose of 20Gy whereas all lung 
tissue which lies within the AP-PA fields must inevitably receive in excess of 20Gy. The 
impact on V20 of treatment field size adjustment to account for target motion in the 3 
principal axes would be quite different in the 2 techniques. Underberg et al. performed 
a similar study looking at the benefit of gating in 15, Stage III NSCLC patients [92]. The 
PTV sizes were comparable to ours however the motion of the tumour in our study was 
marginally more as we specifically selected patients with more motion. They compared 
a number of different plans, but those of interest for comparison are the plans created 
from  the  volumes  encompassing  all  motion  versus  an  end-expiration  gate.  It  is - 126 - 
reassuring they demonstrated similar small reductions in toxicity parameters with an 
absolute reduction in MLD and V20 of 0.9Gy and 1.9% respectively. 
 
There is some suggestion in the literature that RGRT can be used in Stage I tumours 
with stereotactic radiotherapy [153], however the three theoretical benefits of RGRT 
have already been achieved by the development of standard stereotactic radiotherapy 
[12,13,14]. This technique has limited toxicity, can deliver biological equivalent doses 
of 180Gy with excellent local control rates, and all patients are eligible as the volumes 
in Stage I tumours tend to be small. Consequently, reducing the volumes and hence the 
toxicity parameters in Stage I tumours may not be a worthwhile exercise hence, our 
study  concentrated  on  node-positive  lung  cancers  where  the  theoretical  benefits  of 
RGRT have not yet been achieved by other technologies.  
 
There was an additional observation that reducing the set-up margin from 10mm to 
5mm provides a larger reduction in the V20 than RGRT. This raises the question as to 
whether the emphasis in radiotherapy departments should be to improve set-up errors 
using  on-board  imaging  rather  than  implementing  RGRT.  Both  techniques  involve 
increase in work intensity however, online verification techniques can be used for all 
patients where as RGRT is only useful in a minority of patients. Therefore if a centre is 
to implement a technique to decrease toxicity, an online verification technique would 
provide a bigger decrease. 
 
Comparing the benefit of Expiration RGRT versus Inspiration RGRT, we have shown that 
gating has a greater effect on toxicity parameters at end-inspiration. This would be 
consistent with the assumption that the lung volume is expanded and greater sparing is 
possible. Table 6-2 highlights the very marginal improvements at end-expiration. The 
authors feel that should RGRT be applied, end-inspiration is recommended, with an 
awareness  of  its  problems.  However  this  cannot  be  applied  indiscriminately  to  all 
patients and it may be appropriate to assess the possible improvements on a patient by 
patient basis with computer comparison of gating versus continuous (non-gated) 4DCT 
treatment.  - 127 - 
 
In  conclusion,  there  is  a  great  deal  of  interest  in  RGRT  and  its  development  in 
radiotherapy  centres  worldwide,  however  this  study  demonstrates  that  the  vast 
majority  of  patients  are  unlikely  to  have  a  better  clinical  outcome  with  RGRT 
treatment. Due to the additional potential errors involved in RGRT, we feel that until 
further investigation identifies a good method of selecting patients for RGRT, it should 
only be performed if comparative planning of RGRT plans and continuous (non-gated) 
4DCT plans has been undertaken and a likely clinical benefit has been confirmed.  
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7. CONCLUSIONS. 
 
The conclusions to each individual study have been discussed in each chapter in turn. 
There  are  a  number  of  issues  that  the  thesis  as  a  whole  highlights  which  will  be 
discussed below.  
 
This thesis demonstrates how IGRT involves the integration of imaging techniques in all 
three of the stages of radiotherapy; delineation, verification and treatment delivery. In 
addition,  the  thesis  also  highlights  that  each  stage  has  many  different  imaging 
techniques that could be used, usually in combination. For example, in verification, it 
is  apparent  that  each  imaging  technique  is  more  suited  to  identifying  and  limiting 
different types of potential error; MV cine-images are useful for intrafraction tumour 
motion,  while  CBCT  is  the  best  imaging  modality  to  highlight  any  significant 
interfraction tumour motion over the treatment course. The ideal would therefore be 
to  use  the  different  imaging  techniques  in  combination.  The  challenge  in  future 
investigations of IGRT is to identify the combination and timing of different images to 
maximize  tumour  coverage  and  minimise  irradiation  of  normal  tissues.  One  of  the 
hypothetical aims of this thesis was to ensure IGRT could be implemented into a busy 
clinical department. As a result, investigation into the minimal number of each imaging 
technique  would  be  a  useful  research  avenue  to  minimise  the  impact  on  clinical 
departments. 
   
It is apparent that for most technologies used within IGRT, other than SBRT, that there 
is no clinical outcome data. In IGRT, surrogates such as improved target coverage or 
decreased toxicity parameters are used. Primarily, this is because these newer imaging 
techniques address potential errors we were not capable of visualising or quantifying 
before.  Trials  comparing  current  IGRT  techniques  with  previous  methods  would  be 
considered unethical by many, as we would be treating patients while aware there are 
preventable errors. As a result, once a centre has confirmed improved target coverage 
and reduced normal tissue toxicity, departments are happy to implement them into 
clinical care without clinical outcome data. In addition, without implementing IGRT it - 129 - 
is impossible to begin to use other radiotherapy technologies, such as IMRT or SBRT 
which do have good published outcome data. We hope that with the implementation, 
auditing and continuous improving of appropriate IGRT technologies, we will see an 
improvement in local control and overall survival over the coming years. 
 
The  different  outcomes  of  the  different  chapters  emphasise  the  need  to  critically 
analyse  any  new  technique.  RGRT  and  AMTD  are  two  different  techniques  that  are 
implemented and studied. The study in chapter 6 examining AMTD is an initial report 
confirming there are only a small number of patients whose tumours occasionally move 
out with the PTV delineated. It requires further investigation, initially to compare the 
technique  to  standard  delivery  of  radiation  throughout  the  respiratory  cycle  and 
laterally to assess the potential clinical benefit. As discussed above, the outcomes of 
these studies will likely be surrogates of clinical outcome, due to the difficulties of 
using clinical outcome as an endpoint. The RGRT study, suggested there was a minimal 
reduction  in  toxicity  parameters  and  therefore  had  limited  clinical  benefit  to  the 
majority of patients. Both of these studies affirm the need to study and publish results 
on  new  techniques  once  they  have  been  implemented  to  confirm  they  offer  some 
improvement on current techniques.  
 
Lastly,  during  these  investigations,  it  is  evident  that  radical  radiotherapy  for  lung 
cancer should be tailored to each patient. It is not appropriate to have one method of 
treatment for all. The gating study highlights that although RGRT can offer a reduction 
in  toxicity  for  a  few  patients,  it  is  not  clinically  relevant  for  a  vast  majority.  The 
delineation study is in accordance with this finding as it finds the MIP image from the 
4DCT scan can be used in those with Stage I tumours but is not appropriate for those 
with node positive disease.  A further avenue for research in IGRT is how to tailor our 
new  techniques  to  patients  those  who  stand  to  gain  the  most  from  them.  New 
techniques  must  be  investigated  in  specific  homogenous  patient  groups  so  that 
conclusions identify whether or not they are applicable in that patient group.  
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In summary, the era of IGRT is in the early stages. There is so much new technology 
available, but significant careful further study is required to ascertain more regarding 
the role of some techniques and how to implement them into clinical care. Further to 
that,  the  challenge  is  to  identify  the  most  appropriate  combination  of  imaging 
techniques for each individual, in order to achieve the best clinical outcome for every 
patient.  
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